CleftGeneDB-Search

Gene: RUNX2

Basic information

Tag	Content
Uniprot ID	Q13950; O14614; O14615; O95181;
Entrez ID	860
Genbank protein ID	AAA89072.1; AAB65158.1; AAB65159.2; AAC77441.1; AAC78624.1;
Genbank nucleotide ID	NM_001015051.3; NM_001024630.3;
Ensembl protein ID	ENSP00000360486; ENSP00000360493; ENSP00000352514; ENSP00000495497; ENSP00000360491;
Ensembl nucleotide ID	ENSG00000124813
Gene name	Runt-related transcription factor 2
Gene symbol	RUNX2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type	CL/P
Developmental stage
Data sources	Manually collected
Reference	23909516; 22241686; 18357615;
Functional description	Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28738062, PubMed:28703881). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.
Sequence	MASNSLFSTV TPCQQNFFWD PSTSRRFSPP SSSLQPGKMS DVSPVVAAQQ QQQQQQQQQQ 60 QQQQQQQQQQ QEAAAAAAAA AAAAAAAAAV PRLRPPHDNR TMVEIIADHP AELVRTDSPN 120 FLCSVLPSHW RCNKTLPVAF KVVALGEVPD GTVVTVMAGN DENYSAELRN ASAVMKNQVA 180 RFNDLRFVGR SGRGKSFTLT ITVFTNPPQV ATYHRAIKVT VDGPREPRRH RQKLDDSKPS 240 LFSDRLSDLG RIPHPSMRVG VPPQNPRPSL NSAPSPFNPQ GQSQITDPRQ AQSSPPWSYD 300 QSYPSYLSQM TSPSIHSTTP LSSTRGTGLP AITDVPRRIS DDDTATSDFC LWPSTLSKKS 360 QAGASELGPF SDPRQFPSIS SLTESRFSNP RMHYPATFTY TPPVTSGMSL GMSATTHYHT 420 YLPPPYPGSS QSQSGPFQTS STPYLYYGTS SGSYQFPMVP GGDRSPSRML PPCTTTSNGS 480 TLLNPNLPNQ NDGVDADGSH SSSPTVLNSS GRMDESVWRP Y 521

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	RUNX2	102183278	A0A452ETJ7			Capra hircus	Prediction	More>>
1:1 ortholog	RUNX2	860	Q13950	CL/P		Homo sapiens	Publication	More>>
1:1 ortholog	Runx2	12393	Q08775	CPO	E14.5, E16.5	Mus musculus	Publication	More>>
1:1 ortholog	RUNX2		A0A2J8P0L4			Pan troglodytes	Prediction	More>>
1:1 ortholog	Runx2	367218	F1M9C5			Rattus norvegicus	Prediction	More>>
1:1 ortholog	runx2a		F1R272			Danio rerio	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
RUNX2	rs545289	Genotyping; TDT	22241686
RUNX2	rs2153277	Genotyping; TDT	22241686
RUNX2	rs1200426	Genotyping; TDT	22241686
RUNX2	rs1200425	Genotyping; TDT	22241686
RUNX2	rs9395112	Genotyping; TDT	22241686
RUNX2	rs2782660	Genotyping; TDT	22241686
RUNX2	rs1934328	Genotyping; TDT	18357615
RUNX2	rs910586	Genotyping; TDT	18357615
RUNX2	rs2819861	Genotyping; TDT	18357615
RUNX2	rs1934328	Genotyping; TDT	23909516

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
RCV000784917	p.Met1Ile	missense variant	-	NC_000006.12:g.45328729G>A	ClinVar
rs75454554	p.Ser3Leu	missense variant	-	NC_000006.12:g.45328734C>T	ESP,ExAC,gnomAD
rs75454554	p.Ser3Ter	stop gained	-	NC_000006.12:g.45328734C>A	ESP,ExAC,gnomAD
rs541256105	p.Ser5Asn	missense variant	-	NC_000006.12:g.45328740G>A	1000Genomes,ExAC,gnomAD
NCI-TCGA novel	p.Ser8Asn	missense variant	-	NC_000006.12:g.45328749G>A	NCI-TCGA
rs746275240	p.Thr11Ala	missense variant	-	NC_000006.12:g.45328757A>G	ExAC,gnomAD
rs373621180	p.Pro12Leu	missense variant	-	NC_000006.12:g.45328761C>T	ESP,ExAC,TOPMed,gnomAD
rs779487649	p.Pro12Ser	missense variant	-	NC_000006.12:g.45328760C>T	ExAC,gnomAD
rs373621180	p.Pro12Arg	missense variant	-	NC_000006.12:g.45328761C>G	ESP,ExAC,TOPMed,gnomAD
rs1308444345	p.Cys13Arg	missense variant	-	NC_000006.12:g.45328763T>C	TOPMed,gnomAD
rs1308444345	p.Cys13Gly	missense variant	-	NC_000006.12:g.45328763T>G	TOPMed,gnomAD
NCI-TCGA novel	p.Cys13Tyr	missense variant	-	NC_000006.12:g.45328764G>A	NCI-TCGA
rs768149057	p.Gln14Glu	missense variant	-	NC_000006.12:g.45328766C>G	ExAC,TOPMed,gnomAD
rs768149057	p.Gln14Lys	missense variant	-	NC_000006.12:g.45328766C>A	ExAC,TOPMed,gnomAD
rs1441434124	p.Gln15Lys	missense variant	-	NC_000006.12:g.45328769C>A	TOPMed,gnomAD
NCI-TCGA novel	p.Gln15Ter	stop gained	-	NC_000006.12:g.45328769C>T	NCI-TCGA
rs1220365106	p.Phe18Leu	missense variant	-	NC_000006.12:g.45328778T>C	gnomAD
rs1292121646	p.Phe18Ser	missense variant	-	NC_000006.12:g.45328779T>C	gnomAD
rs776156260	p.Asp20Asn	missense variant	-	NC_000006.12:g.45328784G>A	ExAC,gnomAD
rs780033324	p.Pro21Leu	missense variant	-	NC_000006.12:g.45422596C>T	ExAC,gnomAD
rs771988272	p.Pro21Thr	missense variant	-	NC_000006.12:g.45422595C>A	ExAC,gnomAD
rs768497827	p.Ser22Asn	missense variant	-	NC_000006.12:g.45422599G>A	ExAC,gnomAD
rs776729949	p.Thr23Pro	missense variant	-	NC_000006.12:g.45422601A>C	ExAC
rs1384263802	p.Arg25Pro	missense variant	-	NC_000006.12:g.45422608G>C	gnomAD
rs1180264044	p.Arg26His	missense variant	-	NC_000006.12:g.45422611G>A	TOPMed
rs1457634604	p.Phe27Leu	missense variant	-	NC_000006.12:g.45422613T>C	TOPMed
rs114654066	p.Pro29Thr	missense variant	-	NC_000006.12:g.45422619C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs114654066	p.Pro29Ser	missense variant	-	NC_000006.12:g.45422619C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs573668161	p.Pro30Arg	missense variant	-	NC_000006.12:g.45422623C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs990671181	p.Pro30Ala	missense variant	-	NC_000006.12:g.45422622C>G	TOPMed,gnomAD
rs573668161	p.Pro30His	missense variant	-	NC_000006.12:g.45422623C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs990671181	p.Pro30Thr	missense variant	-	NC_000006.12:g.45422622C>A	TOPMed,gnomAD
RCV000055837	p.Ser31Ter	frameshift	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45422624dup	ClinVar
COSM1444867	p.Ser31ProPheSerTerUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45422618C>-	NCI-TCGA Cosmic
rs1336402260	p.Ser32Arg	missense variant	-	NC_000006.12:g.45422630C>A	gnomAD
rs1384459632	p.Ser33Cys	missense variant	-	NC_000006.12:g.45422631A>T	TOPMed,gnomAD
rs534661233	p.Leu34Val	missense variant	-	NC_000006.12:g.45422634C>G	1000Genomes,ExAC,gnomAD
rs1442575261	p.Gln35His	missense variant	-	NC_000006.12:g.45422639G>T	gnomAD
rs1048885121	p.Gln35Arg	missense variant	-	NC_000006.12:g.45422638A>G	TOPMed
rs1048885121	p.Gln35Leu	missense variant	-	NC_000006.12:g.45422638A>T	TOPMed
rs1358936930	p.Gln35Ter	stop gained	-	NC_000006.12:g.45422637C>T	gnomAD
rs1247004200	p.Pro36Ser	missense variant	-	NC_000006.12:g.45422640C>T	TOPMed,gnomAD
rs1247004200	p.Pro36Ala	missense variant	-	NC_000006.12:g.45422640C>G	TOPMed,gnomAD
rs760049118	p.Gly37Arg	missense variant	-	NC_000006.12:g.45422643G>C	ExAC,TOPMed,gnomAD
rs1195139165	p.Met39Thr	missense variant	-	NC_000006.12:g.45422650T>C	gnomAD
rs202042342	p.Asp41Glu	missense variant	-	NC_000006.12:g.45422657C>A	1000Genomes,ExAC,gnomAD
rs200687912	p.Asp41His	missense variant	-	NC_000006.12:g.45422655G>C	TOPMed,gnomAD
rs753332305	p.Val42Leu	missense variant	-	NC_000006.12:g.45422658G>T	ExAC,TOPMed,gnomAD
rs753332305	p.Val42Met	missense variant	-	NC_000006.12:g.45422658G>A	ExAC,TOPMed,gnomAD
rs1013030225	p.Val42Ala	missense variant	-	NC_000006.12:g.45422659T>C	TOPMed
rs1242010684	p.Pro44Leu	missense variant	-	NC_000006.12:g.45422665C>T	gnomAD
rs1242010684	p.Pro44Arg	missense variant	-	NC_000006.12:g.45422665C>G	gnomAD
rs1405128308	p.Val45Gly	missense variant	-	NC_000006.12:g.45422668T>G	TOPMed
rs368475300	p.Gln51Lys	missense variant	-	NC_000006.12:g.45422685C>A	ESP,ExAC,TOPMed,gnomAD
rs1328346387	p.Gln51Arg	missense variant	-	NC_000006.12:g.45422686A>G	gnomAD
RCV000596521	p.Gln51Lys	missense variant	-	NC_000006.12:g.45422685C>A	ClinVar
VAR_064081	p.Gln53Leu	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs758173198	p.Gln54Arg	missense variant	-	NC_000006.12:g.45422695A>G	ExAC,gnomAD
COSM4941172	p.Gln54Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45422695A>C	NCI-TCGA Cosmic
rs1393672497	p.Gln56Ter	stop gained	-	NC_000006.12:g.45422700C>T	gnomAD
rs779943223	p.Gln59Arg	missense variant	-	NC_000006.12:g.45422710A>G	ExAC,TOPMed,gnomAD
rs1490532126	p.Gln64Arg	missense variant	-	NC_000006.12:g.45422725A>G	TOPMed
rs1332669852	p.Gln65Glu	missense variant	-	NC_000006.12:g.45422727C>G	gnomAD
rs1243134950	p.Gln66Arg	missense variant	-	NC_000006.12:g.45422731A>G	gnomAD
rs1286291849	p.Gln67Arg	missense variant	-	NC_000006.12:g.45422734A>G	gnomAD
VAR_079576	p.Gln67_Tyr521del	inframe_deletion	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1356693369	p.Gln68Arg	missense variant	-	NC_000006.12:g.45422737A>G	gnomAD
rs1261964211	p.Gln69Arg	missense variant	-	NC_000006.12:g.45422740A>G	gnomAD
rs769836316	p.Gln69Lys	missense variant	-	NC_000006.12:g.45422739C>A	ExAC,gnomAD
rs1255698663	p.Gln70Leu	missense variant	-	NC_000006.12:g.45422743A>T	gnomAD
rs1461425292	p.Gln70Ter	stop gained	-	NC_000006.12:g.45422742C>T	gnomAD
rs763117080	p.Gln70His	missense variant	-	NC_000006.12:g.45422744G>T	ExAC,TOPMed,gnomAD
rs774631263	p.Gln71Glu	missense variant	-	NC_000006.12:g.45422745C>G	ExAC
rs767984534	p.Glu72Asp	missense variant	-	NC_000006.12:g.45422750G>C	ExAC,TOPMed
rs759833497	p.Glu72Gln	missense variant	-	NC_000006.12:g.45422748G>C	ExAC,gnomAD
RCV000009878	p.Glu72Ter	frameshift	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45422723_45422737delinsACAGCAGCAGCAGCAGCAGCAACAGCAGCCG	ClinVar
rs1374009579	p.Ala73Glu	missense variant	-	NC_000006.12:g.45422752C>A	TOPMed,gnomAD
rs1192865947	p.Ala73Thr	missense variant	-	NC_000006.12:g.45422751G>A	gnomAD
RCV000662189	p.Ala73Ter	frameshift	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45422751del	ClinVar
RCV000662190	p.Ala73Ter	frameshift	Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB)	NC_000006.12:g.45422751del	ClinVar
rs753139240	p.Ala74Glu	missense variant	-	NC_000006.12:g.45422755C>A	ExAC,TOPMed,gnomAD
rs1174985080	p.Ala75Gly	missense variant	-	NC_000006.12:g.45422758C>G	gnomAD
rs1470370276	p.Ala77Val	missense variant	-	NC_000006.12:g.45422764C>T	gnomAD
rs542999615	p.Ala77Thr	missense variant	-	NC_000006.12:g.45422763G>A	1000Genomes,ExAC
rs749974335	p.Ala78Glu	missense variant	-	NC_000006.12:g.45422767C>A	ExAC,TOPMed
rs749974335	p.Ala78Val	missense variant	-	NC_000006.12:g.45422767C>T	ExAC,TOPMed
VAR_012131	p.Ala78_Ala83del	inframe_deletion	-	-	UniProt
rs1383016935	p.Ala79Thr	missense variant	-	NC_000006.12:g.45422769G>A	gnomAD
rs758081090	p.Ala79Val	missense variant	-	NC_000006.12:g.45422770C>T	ExAC,TOPMed,gnomAD
RCV000662187	p.Ala79Ter	frameshift	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45422767_45422768insAGGA	ClinVar
RCV000662188	p.Ala79Ter	frameshift	Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB)	NC_000006.12:g.45422767_45422768insAGGA	ClinVar
rs766130437	p.Ala80Glu	missense variant	-	NC_000006.12:g.45422773C>A	ExAC,TOPMed,gnomAD
rs1231971719	p.Ala81Thr	missense variant	-	NC_000006.12:g.45422775G>A	TOPMed
rs1041352009	p.Ala81Glu	missense variant	-	NC_000006.12:g.45422776C>A	TOPMed
rs781083561	p.Ala82Thr	missense variant	-	NC_000006.12:g.45422778G>A	ExAC,gnomAD
rs1485309580	p.Ala84Val	missense variant	-	NC_000006.12:g.45422785C>T	gnomAD
rs777793369	p.Ala84Thr	missense variant	-	NC_000006.12:g.45422784G>A	ExAC,TOPMed,gnomAD
VAR_012130	p.Ala84insAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAla	repeated_sequence	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs372138746	p.Ala85Val	missense variant	-	NC_000006.12:g.45422788C>T	ESP,ExAC,TOPMed,gnomAD
RCV000435406	p.Ala85Val	missense variant	-	NC_000006.12:g.45422788C>T	ClinVar
rs746166928	p.Ala86Glu	missense variant	-	NC_000006.12:g.45422791C>A	ExAC
rs772291669	p.Ala87Val	missense variant	-	NC_000006.12:g.45422794C>T	ExAC,gnomAD
rs761037120	p.Ala88Thr	missense variant	-	NC_000006.12:g.45422796G>A	ExAC,TOPMed
rs761037120	p.Ala88Ser	missense variant	-	NC_000006.12:g.45422796G>T	ExAC,TOPMed
rs1429247338	p.Val90Leu	missense variant	-	NC_000006.12:g.45422802G>C	gnomAD
rs772777645	p.Arg92Gln	missense variant	-	NC_000006.12:g.45422809G>A	ExAC,gnomAD
rs772777645	p.Arg92Leu	missense variant	-	NC_000006.12:g.45422809G>T	ExAC,gnomAD
rs1386843651	p.Pro95Gln	missense variant	-	NC_000006.12:g.45422818C>A	gnomAD
rs1183896411	p.His97Gln	missense variant	-	NC_000006.12:g.45422825C>A	TOPMed
rs766042547	p.Asp98Gly	missense variant	-	NC_000006.12:g.45422827A>G	ExAC,gnomAD
rs150962268	p.Asn99Ile	missense variant	-	NC_000006.12:g.45422830A>T	ESP,ExAC,TOPMed,gnomAD
rs767171242	p.Arg100Leu	missense variant	-	NC_000006.12:g.45422833G>T	ExAC,gnomAD
rs754711247	p.Arg100Ser	missense variant	-	NC_000006.12:g.45422832C>A	ExAC,gnomAD
rs754711247	p.Arg100Gly	missense variant	-	NC_000006.12:g.45422832C>G	ExAC,gnomAD
rs376849024	p.Met102Val	missense variant	-	NC_000006.12:g.45422838A>G	ESP,ExAC,TOPMed,gnomAD
rs749283473	p.Met102Thr	missense variant	-	NC_000006.12:g.45422839T>C	ExAC,gnomAD
rs1199502681	p.Val103Met	missense variant	-	NC_000006.12:g.45422841G>A	TOPMed
rs1485928187	p.Val103Ala	missense variant	-	NC_000006.12:g.45422842T>C	TOPMed
COSM3874462	p.Glu104Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45422844G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ile105Thr	missense variant	-	NC_000006.12:g.45422848T>C	NCI-TCGA
rs528470044	p.Ala107Val	missense variant	-	NC_000006.12:g.45422854C>T	1000Genomes
rs1490639289	p.His109Tyr	missense variant	-	NC_000006.12:g.45422859C>T	gnomAD
rs1352066437	p.His109Leu	missense variant	-	NC_000006.12:g.45422860A>T	TOPMed
rs1490639289	p.His109Asn	missense variant	-	NC_000006.12:g.45422859C>A	gnomAD
rs150088136	p.Pro110Leu	missense variant	-	NC_000006.12:g.45422863C>T	ESP,ExAC,TOPMed
rs1342614199	p.Ala111Gly	missense variant	-	NC_000006.12:g.45422866C>G	TOPMed
rs1418628831	p.Glu112Lys	missense variant	-	NC_000006.12:g.45422868G>A	gnomAD
VAR_012132	p.Leu113Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs762474281	p.Asp117Tyr	missense variant	-	NC_000006.12:g.45422883G>T	ExAC,TOPMed,gnomAD
rs762474281	p.Asp117His	missense variant	-	NC_000006.12:g.45422883G>C	ExAC,TOPMed,gnomAD
rs762474281	p.Asp117Asn	missense variant	-	NC_000006.12:g.45422883G>A	ExAC,TOPMed,gnomAD
VAR_064082	p.Ser118Asn	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_012133	p.Ser118Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_012134	p.Phe121Cys	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_012135	p.Cys123Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1371950698	p.Pro127Thr	missense variant	-	NC_000006.12:g.45422913C>A	gnomAD
NCI-TCGA novel	p.Trp130Cys	missense variant	-	NC_000006.12:g.45422924G>T	NCI-TCGA
rs1308549222	p.Arg131His	missense variant	-	NC_000006.12:g.45422926G>A	gnomAD
NCI-TCGA novel	p.Arg131Cys	missense variant	-	NC_000006.12:g.45422925C>T	NCI-TCGA
VAR_064085	p.Arg131Ser	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064083	p.Arg131Cys	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064084	p.Arg131Gly	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1356764547	p.Asn133Ser	missense variant	-	NC_000006.12:g.45422932A>G	gnomAD
VAR_012136	p.Asn133del	inframe_deletion	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064086	p.Leu136Pro	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs760449546	p.Ala139Thr	missense variant	-	NC_000006.12:g.45422949G>A	ExAC,gnomAD
rs1473913096	p.Val142Leu	missense variant	-	NC_000006.12:g.45431863G>T	gnomAD
rs759100705	p.Leu145Phe	missense variant	-	NC_000006.12:g.45431872C>T	ExAC,gnomAD
rs1428979499	p.Gly146Arg	missense variant	-	NC_000006.12:g.45431875G>A	gnomAD
rs370512978	p.Glu147Lys	missense variant	-	NC_000006.12:g.45431878G>A	ESP,ExAC,gnomAD
rs760361518	p.Glu147Asp	missense variant	-	NC_000006.12:g.45431880G>C	ExAC,gnomAD
NCI-TCGA novel	p.Glu147Ter	missense variant	-	NC_000006.12:g.45431878G>T	NCI-TCGA
rs763852761	p.Pro149Ser	missense variant	-	NC_000006.12:g.45431884C>T	ExAC,gnomAD
rs1360487110	p.Gly151Ala	missense variant	-	NC_000006.12:g.45431891G>C	gnomAD
rs373029816	p.Thr152Ile	missense variant	-	NC_000006.12:g.45431894C>T	ESP,ExAC,TOPMed,gnomAD
COSM1079805	p.Thr155Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45431903C>T	NCI-TCGA Cosmic
VAR_064088	p.Val156Gly	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064087	p.Val156Asp	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1426085360	p.Met157Thr	missense variant	-	NC_000006.12:g.45431909T>C	TOPMed
COSM1079807	p.Ala158Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45431912C>T	NCI-TCGA Cosmic
rs864621970	p.Gly159Asp	missense variant	-	NC_000006.12:g.45431915G>A	-
RCV000206373	p.Gly159Asp	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45431915G>A	ClinVar
COSM1079809	p.Asn160ThrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45431916T>-	NCI-TCGA Cosmic
rs1477047335	p.Asp161Asn	missense variant	-	NC_000006.12:g.45431920G>A	TOPMed
NCI-TCGA novel	p.Asp161Glu	missense variant	-	NC_000006.12:g.45431922T>A	NCI-TCGA
rs780062825	p.Glu162Gly	missense variant	-	NC_000006.12:g.45431924A>G	ExAC,gnomAD
COSM1079811	p.Asn163Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45431928T>G	NCI-TCGA Cosmic
rs1203066173	p.Arg169Trp	missense variant	-	NC_000006.12:g.45431944C>T	gnomAD
rs104893995	p.Arg169Pro	missense variant	-	NC_000006.12:g.45431945G>C	ExAC,gnomAD
rs104893995	p.Arg169Pro	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431945G>C	UniProt,dbSNP
VAR_064089	p.Arg169Pro	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431945G>C	UniProt
rs104893995	p.Arg169Gln	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431945G>A	UniProt,dbSNP
VAR_012137	p.Arg169Gln	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431945G>A	UniProt
rs104893995	p.Arg169Gln	missense variant	-	NC_000006.12:g.45431945G>A	ExAC,gnomAD
RCV000009890	p.Arg169Pro	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45431945G>C	ClinVar
rs1001873615	p.Asn170Lys	missense variant	-	NC_000006.12:g.45431949T>G	TOPMed
rs568476296	p.Val174Ala	missense variant	-	NC_000006.12:g.45431960T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs201647225	p.Met175Val	missense variant	-	NC_000006.12:g.45431962A>G	ExAC,TOPMed,gnomAD
rs104893989	p.Met175Arg	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431963T>G	UniProt,dbSNP
VAR_012138	p.Met175Arg	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45431963T>G	UniProt
rs104893989	p.Met175Arg	missense variant	-	NC_000006.12:g.45431963T>G	ExAC,gnomAD
rs104893989	p.Met175Thr	missense variant	-	NC_000006.12:g.45431963T>C	ExAC,gnomAD
RCV000009881	p.Met175Arg	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45431963T>G	ClinVar
VAR_064090	p.Met175Lys	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs147359883	p.Asn177Lys	missense variant	-	NC_000006.12:g.45431970C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs147359883	p.Asn177Lys	missense variant	-	NC_000006.12:g.45431970C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000278819	p.Asn177Lys	missense variant	-	NC_000006.12:g.45431970C>G	ClinVar
rs1195717789	p.Gln178Arg	missense variant	-	NC_000006.12:g.45431972A>G	gnomAD
rs182416246	p.Val179Leu	missense variant	-	NC_000006.12:g.45431974G>C	1000Genomes,ExAC,gnomAD
rs1480082466	p.Ala180Thr	missense variant	-	NC_000006.12:g.45431977G>A	gnomAD
NCI-TCGA novel	p.Arg181IlePheSerTerUnkUnk	frameshift	-	NC_000006.12:g.45431980_45431981insTAAT	NCI-TCGA
NCI-TCGA novel	p.Phe182HisPheSerTerUnk	frameshift	-	NC_000006.12:g.45431982_45431983insCACATCAGAAAGGC	NCI-TCGA
rs115974315	p.Asn183Lys	missense variant	-	NC_000006.12:g.45431988C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM1165767	p.Asp184Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45431989G>A	NCI-TCGA Cosmic
COSM3830654	p.Arg186Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45431996G>T	NCI-TCGA Cosmic
VAR_079577	p.Arg186Thr	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064092	p.Phe187Ser	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1057521068	p.Arg190Gln	missense variant	-	NC_000006.12:g.45432008G>A	-
COSM1079813	p.Arg190Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45432007C>T	NCI-TCGA Cosmic
RCV000430285	p.Arg190Gln	missense variant	-	NC_000006.12:g.45432008G>A	ClinVar
VAR_012140	p.Arg190Trp	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
RCV000009882	p.Ser191Asn	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45432011G>A	ClinVar
rs104893990	p.Ser191Asn	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45432011G>A	UniProt,dbSNP
VAR_012141	p.Ser191Asn	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45432011G>A	UniProt
rs104893990	p.Ser191Asn	missense variant	-	NC_000006.12:g.45432011G>A	-
NCI-TCGA novel	p.Ser191TrpPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.45432000_45432001insGTGGGCCG	NCI-TCGA
COSM1487800	p.Gly192Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45432013G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Arg193Ter	stop gained	-	NC_000006.12:g.45432016C>T	NCI-TCGA
NCI-TCGA novel	p.Arg193Gln	missense variant	-	NC_000006.12:g.45432017G>A	NCI-TCGA
VAR_079578	p.Arg193Gly	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_012142	p.Arg193Cys	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064093	p.Arg193Gln	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
NCI-TCGA novel	p.Lys195Asn	missense variant	-	NC_000006.12:g.45437951G>C	NCI-TCGA
NCI-TCGA novel	p.Lys195Met	missense variant	-	NC_000006.12:g.45437950A>T	NCI-TCGA
VAR_012143	p.Phe197Ser	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_012144	p.Leu199Phe	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs104893993	p.Thr200Ala	missense variant	-	NC_000006.12:g.45437964A>G	-
rs104893993	p.Thr200Ala	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45437964A>G	UniProt,dbSNP
VAR_012145	p.Thr200Ala	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45437964A>G	UniProt
RCV000009888	p.Thr200Ala	missense variant	Cleidocranial dysplasia, forme fruste, dental anomalies only	NC_000006.12:g.45437964A>G	ClinVar
RCV000009887	p.Thr200Ala	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45437964A>G	ClinVar
VAR_064094	p.Thr200Ile	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064095	p.Ile201Lys	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
NCI-TCGA novel	p.Thr202Ala	missense variant	-	NC_000006.12:g.45437970A>G	NCI-TCGA
rs147009083	p.Val203Ile	missense variant	-	NC_000006.12:g.45437973G>A	ESP,ExAC,TOPMed,gnomAD
rs772926106	p.Phe204Cys	missense variant	-	NC_000006.12:g.45437977T>G	ExAC,gnomAD
rs762910660	p.Thr205Ala	missense variant	-	NC_000006.12:g.45437979A>G	ExAC,gnomAD
VAR_012146	p.Thr205Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
NCI-TCGA novel	p.Pro207Ser	missense variant	-	NC_000006.12:g.45437985C>T	NCI-TCGA
NCI-TCGA novel	p.Pro208Ser	missense variant	-	NC_000006.12:g.45437988C>T	NCI-TCGA
VAR_012147	p.Gln209Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064096	p.Gln209His	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1305465503	p.Ala211Ser	missense variant	-	NC_000006.12:g.45437997G>T	TOPMed
VAR_064097	p.Ala211Pro	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
NCI-TCGA novel	p.Thr212Asn	missense variant	-	NC_000006.12:g.45438001C>A	NCI-TCGA
rs138138469	p.Tyr213Cys	missense variant	-	NC_000006.12:g.45438004A>G	ESP,ExAC,TOPMed,gnomAD
rs774518258	p.His214Gln	missense variant	-	NC_000006.12:g.45438008C>G	ExAC,gnomAD
rs759679284	p.Arg215Ser	missense variant	-	NC_000006.12:g.45438011A>T	ExAC,gnomAD
rs752933596	p.Lys218Asn	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438020A>T	UniProt,dbSNP
VAR_064099	p.Lys218Asn	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438020A>T	UniProt
rs752933596	p.Lys218Asn	missense variant	-	NC_000006.12:g.45438020A>T	ExAC,gnomAD
VAR_064100	p.Lys218Gln	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064098	p.Lys218Glu	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1217642791	p.Val219Ile	missense variant	-	NC_000006.12:g.45438021G>A	gnomAD
VAR_064101	p.Thr220Ile	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
NCI-TCGA novel	p.Asp222His	missense variant	-	NC_000006.12:g.45438030G>C	NCI-TCGA
rs1325045940	p.Pro224His	missense variant	-	NC_000006.12:g.45438037C>A	TOPMed
rs104893992	p.Arg225Trp	missense variant	-	NC_000006.12:g.45438039C>T	-
rs104893992	p.Arg225Trp	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438039C>T	UniProt,dbSNP
VAR_012149	p.Arg225Trp	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438039C>T	UniProt
rs104893991	p.Arg225Gln	missense variant	-	NC_000006.12:g.45438040G>A	-
rs104893991	p.Arg225Gln	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438040G>A	UniProt,dbSNP
VAR_012148	p.Arg225Gln	missense variant	Cleidocranial dysplasia (CLCD)	NC_000006.12:g.45438040G>A	UniProt
RCV000009885	p.Arg225Gln	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45438040G>A	ClinVar
RCV000731332	p.Arg225Gln	missense variant	-	NC_000006.12:g.45438040G>A	ClinVar
NCI-TCGA novel	p.Arg225Leu	missense variant	-	NC_000006.12:g.45438040G>T	NCI-TCGA
RCV000009886	p.Arg225Trp	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45438039C>T	ClinVar
VAR_064102	p.Arg225Leu	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064103	p.Arg228Gly	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs765653239	p.His230Asn	missense variant	-	NC_000006.12:g.45491943C>A	ExAC,gnomAD
rs1405556189	p.Gln232Glu	missense variant	-	NC_000006.12:g.45491949C>G	gnomAD
VAR_064104	p.Lys233Arg	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1289838464	p.Leu234Pro	missense variant	-	NC_000006.12:g.45491956T>C	TOPMed
rs373709122	p.Asp235His	missense variant	-	NC_000006.12:g.45491958G>C	ESP,ExAC,gnomAD
rs780701424	p.Asp235Gly	missense variant	-	NC_000006.12:g.45491959A>G	ExAC,gnomAD
rs180860949	p.Asp236Val	missense variant	-	NC_000006.12:g.45491962A>T	1000Genomes
rs186720964	p.Pro239Leu	missense variant	-	NC_000006.12:g.45491971C>T	1000Genomes
rs752156180	p.Pro239Ser	missense variant	-	NC_000006.12:g.45491970C>T	ExAC,gnomAD
rs752156180	p.Pro239Thr	missense variant	-	NC_000006.12:g.45491970C>A	ExAC,gnomAD
rs749040759	p.Ser240Arg	missense variant	-	NC_000006.12:g.45491975T>A	ExAC,gnomAD
rs1319345318	p.Ser240Asn	missense variant	-	NC_000006.12:g.45491974G>A	TOPMed,gnomAD
rs770818987	p.Ser243Cys	missense variant	-	NC_000006.12:g.45491983C>G	ExAC,gnomAD
rs778901535	p.Asp244Glu	missense variant	-	NC_000006.12:g.45491987C>A	ExAC,gnomAD
rs1354561966	p.Asp244His	missense variant	-	NC_000006.12:g.45491985G>C	TOPMed
rs1201891556	p.Arg245Cys	missense variant	-	NC_000006.12:g.45491988C>T	gnomAD
rs1310889814	p.Arg245His	missense variant	-	NC_000006.12:g.45491989G>A	TOPMed
NCI-TCGA novel	p.Arg245Leu	missense variant	-	NC_000006.12:g.45491989G>T	NCI-TCGA
rs745752587	p.Leu246Pro	missense variant	-	NC_000006.12:g.45491992T>C	ExAC,gnomAD
NCI-TCGA novel	p.Ser247Ile	missense variant	-	NC_000006.12:g.45491995G>T	NCI-TCGA
rs11498200	p.Arg251Cys	missense variant	-	NC_000006.12:g.45492006C>T	ExAC,TOPMed,gnomAD
rs11498200	p.Arg251Ser	missense variant	-	NC_000006.12:g.45492006C>A	ExAC,TOPMed,gnomAD
rs376891808	p.Arg251His	missense variant	-	NC_000006.12:g.45492007G>A	ESP,ExAC,gnomAD
rs377128508	p.His254Arg	missense variant	-	NC_000006.12:g.45492016A>G	ESP,ExAC,gnomAD
rs1158008972	p.Pro255His	missense variant	-	NC_000006.12:g.45492019C>A	TOPMed
rs776708490	p.Ser256Thr	missense variant	-	NC_000006.12:g.45492022G>C	ExAC,TOPMed,gnomAD
rs776708490	p.Ser256Ile	missense variant	-	NC_000006.12:g.45492022G>T	ExAC,TOPMed,gnomAD
rs1414370387	p.Met257Thr	missense variant	-	NC_000006.12:g.45492025T>C	TOPMed
rs1428685613	p.Arg258Ile	missense variant	-	NC_000006.12:g.45492028G>T	gnomAD
rs1466738996	p.Val259Ile	missense variant	-	NC_000006.12:g.45492030G>A	TOPMed,gnomAD
rs762058135	p.Val261Ile	missense variant	-	NC_000006.12:g.45492036G>A	ExAC,gnomAD
COSM1079815	p.Val261Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45492037T>C	NCI-TCGA Cosmic
rs563772449	p.Pro263His	missense variant	-	NC_000006.12:g.45492043C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs563772449	p.Pro263Leu	missense variant	-	NC_000006.12:g.45492043C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1221616975	p.Asn265His	missense variant	-	NC_000006.12:g.45492048A>C	gnomAD
rs1234937174	p.Arg267Gln	missense variant	-	NC_000006.12:g.45492055G>A	gnomAD
rs370486033	p.Arg267Trp	missense variant	-	NC_000006.12:g.45492054C>T	ESP,ExAC,TOPMed,gnomAD
rs766812325	p.Pro268Arg	missense variant	-	NC_000006.12:g.45492058C>G	ExAC
rs1190085215	p.Asn271Asp	missense variant	-	NC_000006.12:g.45492066A>G	TOPMed
rs1443448373	p.Ala273Pro	missense variant	-	NC_000006.12:g.45492072G>C	TOPMed
rs1443448373	p.Ala273Thr	missense variant	-	NC_000006.12:g.45492072G>A	TOPMed
rs1349550429	p.Pro274Thr	missense variant	-	NC_000006.12:g.45492075C>A	gnomAD
rs755578627	p.Pro276Ser	missense variant	-	NC_000006.12:g.45492081C>T	ExAC,gnomAD
rs1203966568	p.Pro276Arg	missense variant	-	NC_000006.12:g.45492082C>G	TOPMed
rs1463155276	p.Asn278Ile	missense variant	-	NC_000006.12:g.45492088A>T	TOPMed
rs1489516989	p.Gln282Arg	missense variant	-	NC_000006.12:g.45492100A>G	gnomAD
rs1033729267	p.Asp287Gly	missense variant	-	NC_000006.12:g.45512246A>G	-
RCV000482841	p.Asp287Gly	missense variant	-	NC_000006.12:g.45512246A>G	ClinVar
VAR_064105	p.Asp287Asn	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1179560763	p.Pro288Ser	missense variant	-	NC_000006.12:g.45512248C>T	gnomAD
rs148326029	p.Pro288Leu	missense variant	-	NC_000006.12:g.45512249C>T	ESP,ExAC,TOPMed,gnomAD
rs1311296877	p.Gln290Lys	missense variant	-	NC_000006.12:g.45512254C>A	gnomAD
rs760143015	p.Gln290His	missense variant	-	NC_000006.12:g.45512256G>C	ExAC,gnomAD
rs1244922471	p.Ala291Pro	missense variant	-	NC_000006.12:g.45512257G>C	gnomAD
rs763466386	p.Pro295Arg	missense variant	-	NC_000006.12:g.45512270C>G	ExAC,TOPMed,gnomAD
rs763466386	p.Pro295Leu	missense variant	-	NC_000006.12:g.45512270C>T	ExAC,TOPMed,gnomAD
rs1554397657	p.Pro296Ser	missense variant	-	NC_000006.12:g.45512272C>T	-
RCV000507803	p.Pro296Ser	missense variant	-	NC_000006.12:g.45512272C>T	ClinVar
rs201584115	p.Pro296Leu	missense variant	-	NC_000006.12:g.45512273C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000374592	p.Pro296Leu	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45512273C>T	ClinVar
rs104893988	p.Trp297Ter	stop gained	-	NC_000006.12:g.45512277G>A	-
RCV000009879	p.Trp297Ter	nonsense	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45512277G>A	ClinVar
rs370331024	p.Asp300His	missense variant	-	NC_000006.12:g.45512284G>C	ESP,ExAC,TOPMed,gnomAD
rs1447043793	p.Asp300Val	missense variant	-	NC_000006.12:g.45512285A>T	gnomAD
rs779939748	p.Gln301Arg	missense variant	-	NC_000006.12:g.45512288A>G	ExAC,TOPMed,gnomAD
rs758120505	p.Gln301Glu	missense variant	-	NC_000006.12:g.45512287C>G	ExAC,TOPMed,gnomAD
rs1312487890	p.Ser302Phe	missense variant	-	NC_000006.12:g.45512291C>T	gnomAD
rs746897678	p.Ser302Ala	missense variant	-	NC_000006.12:g.45512290T>G	ExAC,gnomAD
rs754963913	p.Tyr303Phe	missense variant	-	NC_000006.12:g.45512294A>T	ExAC,gnomAD
rs748242152	p.Pro304Arg	missense variant	-	NC_000006.12:g.45512297C>G	ExAC,TOPMed,gnomAD
rs781207125	p.Pro304Ser	missense variant	-	NC_000006.12:g.45512296C>T	ExAC,TOPMed,gnomAD
rs748242152	p.Pro304Leu	missense variant	-	NC_000006.12:g.45512297C>T	ExAC,TOPMed,gnomAD
rs769922027	p.Ser305Cys	missense variant	-	NC_000006.12:g.45512300C>G	ExAC,gnomAD
rs1199475592	p.Tyr306Ser	missense variant	-	NC_000006.12:g.45512303A>C	gnomAD
rs1181014657	p.Ser308Arg	missense variant	-	NC_000006.12:g.45512310C>G	gnomAD
rs1443036287	p.Ser308Arg	missense variant	-	NC_000006.12:g.45512308A>C	gnomAD
COSM6106996	p.Gln309Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45512311C>G	NCI-TCGA Cosmic
rs1414266851	p.Met310Thr	missense variant	-	NC_000006.12:g.45512315T>C	gnomAD
rs749565421	p.Thr311Met	missense variant	-	NC_000006.12:g.45512318C>T	ExAC,TOPMed,gnomAD
COSM4839324	p.Ser312Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45512321C>T	NCI-TCGA Cosmic
rs535706340	p.Pro313Arg	missense variant	-	NC_000006.12:g.45512324C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs774805163	p.Pro313Ala	missense variant	-	NC_000006.12:g.45512323C>G	ExAC,gnomAD
rs535706340	p.Pro313Gln	missense variant	-	NC_000006.12:g.45512324C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs535706340	p.Pro313Leu	missense variant	-	NC_000006.12:g.45512324C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs776221631	p.Ser314Pro	missense variant	-	NC_000006.12:g.45512326T>C	ExAC,gnomAD
rs1451478006	p.Ser314Phe	missense variant	-	NC_000006.12:g.45512327C>T	gnomAD
rs761391105	p.Thr318Ala	missense variant	-	NC_000006.12:g.45512338A>G	ExAC,gnomAD
NCI-TCGA novel	p.Thr318Ser	missense variant	-	NC_000006.12:g.45512338A>T	NCI-TCGA
rs746114073	p.Pro320Leu	missense variant	-	NC_000006.12:g.45512345C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu321AlaPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.45512341_45512342insC	NCI-TCGA
rs751400416	p.Arg325Trp	missense variant	-	NC_000006.12:g.45512359C>T	ExAC,TOPMed,gnomAD
COSM5870801	p.Arg325Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45512360G>A	NCI-TCGA Cosmic
rs1476037778	p.Gly326Ser	missense variant	-	NC_000006.12:g.45512362G>A	TOPMed
rs143092997	p.Gly326Val	missense variant	-	NC_000006.12:g.45512363G>T	ESP,ExAC,gnomAD
rs781096197	p.Pro330His	missense variant	-	NC_000006.12:g.45512375C>A	ExAC,gnomAD
rs1382629082	p.Pro330Ser	missense variant	-	NC_000006.12:g.45512374C>T	TOPMed,gnomAD
rs114554762	p.Ala331Asp	missense variant	-	NC_000006.12:g.45512378C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs114554762	p.Ala331Gly	missense variant	-	NC_000006.12:g.45512378C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala331Val	missense variant	-	NC_000006.12:g.45512378C>T	NCI-TCGA
rs749426825	p.Asp334Ala	missense variant	-	NC_000006.12:g.45512387A>C	ExAC,gnomAD
rs373752642	p.Asp334Asn	missense variant	-	NC_000006.12:g.45512386G>A	ESP,ExAC,TOPMed,gnomAD
rs373752642	p.Asp334His	missense variant	-	NC_000006.12:g.45512386G>C	ESP,ExAC,TOPMed,gnomAD
rs749426825	p.Asp334Gly	missense variant	-	NC_000006.12:g.45512387A>G	ExAC,gnomAD
rs1426595686	p.Val335Ala	missense variant	-	NC_000006.12:g.45512390T>C	TOPMed,gnomAD
rs771219239	p.Val335Met	missense variant	-	NC_000006.12:g.45512389G>A	ExAC,gnomAD
rs1366398692	p.Pro336Leu	missense variant	-	NC_000006.12:g.45512393C>T	TOPMed,gnomAD
COSM345850	p.Arg337Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45512396G>T	NCI-TCGA Cosmic
rs779082630	p.Arg338Cys	missense variant	-	NC_000006.12:g.45512398C>T	ExAC,TOPMed,gnomAD
rs367898326	p.Arg338His	missense variant	-	NC_000006.12:g.45512399G>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg338Gly	missense variant	-	NC_000006.12:g.45512398C>G	NCI-TCGA
COSM3830656	p.Ser340Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45512405C>A	NCI-TCGA Cosmic
rs1388460369	p.Asp341Glu	missense variant	-	NC_000006.12:g.45545218T>A	TOPMed
rs1369927853	p.Asp341Gly	missense variant	-	NC_000006.12:g.45545217A>G	gnomAD
COSM1079821	p.Asp341Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45512407G>T	NCI-TCGA Cosmic
rs1222286451	p.Asp342Asn	missense variant	-	NC_000006.12:g.45545219G>A	gnomAD
rs1354211513	p.Thr344Ile	missense variant	-	NC_000006.12:g.45545226C>T	gnomAD
rs1289456738	p.Pro353Ser	missense variant	-	NC_000006.12:g.45545252C>T	gnomAD
rs1254496350	p.Pro353Leu	missense variant	-	NC_000006.12:g.45545253C>T	gnomAD
rs1450988498	p.Thr355Ala	missense variant	-	NC_000006.12:g.45545258A>G	gnomAD
rs1468281184	p.Ser360Gly	missense variant	-	NC_000006.12:g.45545273A>G	gnomAD
rs1177692351	p.Ser360Thr	missense variant	-	NC_000006.12:g.45545274G>C	gnomAD
rs1297710073	p.Gln361Leu	missense variant	-	NC_000006.12:g.45545277A>T	TOPMed
VAR_064106	p.Ala362Val	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
COSM742793	p.Glu366Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45546835G>T	NCI-TCGA Cosmic
rs140165241	p.Leu367Val	missense variant	-	NC_000006.12:g.45546838C>G	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Gly368AlaPheSerTerUnkUnkUnk	frameshift	-	NC_000006.12:g.45546840G>-	NCI-TCGA
rs767251365	p.Pro369Arg	missense variant	-	NC_000006.12:g.45546845C>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Asp372Tyr	missense variant	-	NC_000006.12:g.45546853G>T	NCI-TCGA
NCI-TCGA novel	p.Asp372Val	missense variant	-	NC_000006.12:g.45546854A>T	NCI-TCGA
rs1401233132	p.Pro373Arg	missense variant	-	NC_000006.12:g.45546857C>G	gnomAD
rs752525068	p.Ser378Gly	missense variant	-	NC_000006.12:g.45546871A>G	ExAC,gnomAD
rs760543307	p.Ser378Arg	missense variant	-	NC_000006.12:g.45546873C>A	ExAC,gnomAD
rs1339712379	p.Ser380Leu	missense variant	-	NC_000006.12:g.45546878C>T	gnomAD
rs1341793914	p.Ser381Phe	missense variant	-	NC_000006.12:g.45546881C>T	TOPMed
rs757351966	p.Arg386His	missense variant	-	NC_000006.12:g.45546896G>A	ExAC,TOPMed,gnomAD
rs753780685	p.Arg386Cys	missense variant	-	NC_000006.12:g.45546895C>T	ExAC,TOPMed,gnomAD
rs1388215851	p.Asn389His	missense variant	-	NC_000006.12:g.45546904A>C	TOPMed
rs115347084	p.Asn389Ser	missense variant	-	NC_000006.12:g.45546905A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Pro390Ser	missense variant	-	NC_000006.12:g.45546907C>T	NCI-TCGA
rs780524636	p.Arg391Gln	missense variant	-	NC_000006.12:g.45546911G>A	ExAC,gnomAD
rs397515537	p.Arg391Ter	stop gained	-	NC_000006.12:g.45546910C>T	-
RCV000055836	p.Arg391Ter	nonsense	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45546910C>T	ClinVar
rs1461715414	p.Tyr394Asp	missense variant	-	NC_000006.12:g.45546919T>G	TOPMed
rs747380594	p.Tyr394Phe	missense variant	-	NC_000006.12:g.45546920A>T	ExAC,gnomAD
rs755482498	p.Pro395Gln	missense variant	-	NC_000006.12:g.45546923C>A	ExAC,gnomAD
rs1022790945	p.Ala396Val	missense variant	-	NC_000006.12:g.45546926C>T	gnomAD
rs1477135017	p.Tyr400Cys	missense variant	-	NC_000006.12:g.45546938A>G	gnomAD
VAR_079579	p.Tyr400_Tyr521del	inframe_deletion	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs748644984	p.Thr401Pro	missense variant	-	NC_000006.12:g.45546940A>C	ExAC,gnomAD
rs770452837	p.Pro402Leu	missense variant	-	NC_000006.12:g.45546944C>T	ExAC,gnomAD
rs376694142	p.Pro403Leu	missense variant	-	NC_000006.12:g.45546947C>T	ESP,ExAC,TOPMed,gnomAD
RCV000009884	p.Pro403Ter	frameshift	Cleidocranial dysplasia, severe, with osteoporosis and scoliosis	NC_000006.12:g.45546944dup	ClinVar
rs1269813407	p.Gly407Cys	missense variant	-	NC_000006.12:g.45546958G>T	TOPMed
rs1032694844	p.Met408Val	missense variant	-	NC_000006.12:g.45546961A>G	TOPMed,gnomAD
NCI-TCGA novel	p.Leu410Phe	missense variant	-	NC_000006.12:g.45546967C>T	NCI-TCGA
RCV000009891	p.Leu410Ter	frameshift	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45546967dup	ClinVar
rs1338264589	p.Gly411Val	missense variant	-	NC_000006.12:g.45546971G>T	gnomAD
rs763860044	p.Ala414Thr	missense variant	-	NC_000006.12:g.45546979G>A	ExAC,TOPMed,gnomAD
COSM3874472	p.Thr415Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45546982A>G	NCI-TCGA Cosmic
rs1024556116	p.Thr416Ser	missense variant	-	NC_000006.12:g.45546986C>G	TOPMed
rs1319458779	p.His417Asp	missense variant	-	NC_000006.12:g.45546988C>G	gnomAD
VAR_064108	p.Thr420Asn	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
VAR_064107	p.Thr420Ile	Missense	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1255011742	p.Tyr421Phe	missense variant	-	NC_000006.12:g.45547001A>T	TOPMed,gnomAD
rs1345306388	p.Leu422Met	missense variant	-	NC_000006.12:g.45547003C>A	gnomAD
NCI-TCGA novel	p.Pro424Gln	missense variant	-	NC_000006.12:g.45547010C>A	NCI-TCGA
rs761701398	p.Pro425Leu	missense variant	-	NC_000006.12:g.45547013C>T	ExAC,gnomAD
rs1305087594	p.Pro425Thr	missense variant	-	NC_000006.12:g.45547012C>A	TOPMed
NCI-TCGA novel	p.Pro425Ser	missense variant	-	NC_000006.12:g.45547012C>T	NCI-TCGA
RCV000486764	p.Tyr426Ter	frameshift	-	NC_000006.12:g.45547014dup	ClinVar
rs765308202	p.Pro427Leu	missense variant	-	NC_000006.12:g.45547019C>T	ExAC,gnomAD
rs758626590	p.Gly428Ser	missense variant	-	NC_000006.12:g.45547021G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly428Asp	missense variant	-	NC_000006.12:g.45547022G>A	NCI-TCGA
rs1196892781	p.Gln431Arg	missense variant	-	NC_000006.12:g.45547031A>G	gnomAD
rs144760627	p.Ser432Arg	missense variant	-	NC_000006.12:g.45547035C>A	ESP,TOPMed
rs1377237744	p.Gln433Arg	missense variant	-	NC_000006.12:g.45547037A>G	gnomAD
rs1210047580	p.Ser434Asn	missense variant	-	NC_000006.12:g.45547040G>A	gnomAD
rs1172059142	p.Pro436Ser	missense variant	-	NC_000006.12:g.45547045C>T	TOPMed
rs751887748	p.Pro436Leu	missense variant	-	NC_000006.12:g.45547046C>T	ExAC,TOPMed,gnomAD
rs751887748	p.Pro436His	missense variant	-	NC_000006.12:g.45547046C>A	ExAC,TOPMed,gnomAD
rs748640088	p.Thr439Pro	missense variant	-	NC_000006.12:g.45547054A>C	ExAC,gnomAD
rs748640088	p.Thr439Ala	missense variant	-	NC_000006.12:g.45547054A>G	ExAC,gnomAD
NCI-TCGA novel	p.Thr439Asn	missense variant	-	NC_000006.12:g.45547055C>A	NCI-TCGA
rs974164696	p.Ser441Arg	missense variant	-	NC_000006.12:g.45547062C>A	TOPMed,gnomAD
rs974164696	p.Ser441Arg	missense variant	-	NC_000006.12:g.45547062C>G	TOPMed,gnomAD
COSM742791	p.Thr442Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45547064C>G	NCI-TCGA Cosmic
rs1180944672	p.Leu445Val	missense variant	-	NC_000006.12:g.45547072C>G	TOPMed
COSM1079823	p.Leu445Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45547072C>A	NCI-TCGA Cosmic
rs1384517929	p.Gly448Cys	missense variant	-	NC_000006.12:g.45547081G>T	TOPMed,gnomAD
rs369481795	p.Ser450Leu	missense variant	-	NC_000006.12:g.45547088C>T	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ser450Ter	stop gained	-	NC_000006.12:g.45547088C>A	NCI-TCGA
NCI-TCGA novel	p.Ser450TyrPheSerTerUnkUnk	frameshift	-	NC_000006.12:g.45547087_45547088insA	NCI-TCGA
rs1235041904	p.Gly452Arg	missense variant	-	NC_000006.12:g.45547093G>C	TOPMed,gnomAD
rs771630924	p.Ser453Phe	missense variant	-	NC_000006.12:g.45547097C>T	ExAC,gnomAD
rs1234539221	p.Tyr454His	missense variant	-	NC_000006.12:g.45547099T>C	TOPMed
rs1216479084	p.Tyr454Cys	missense variant	-	NC_000006.12:g.45547100A>G	TOPMed,gnomAD
rs1216479084	p.Tyr454Phe	missense variant	-	NC_000006.12:g.45547100A>T	TOPMed,gnomAD
rs1182756497	p.Gln455Pro	missense variant	-	NC_000006.12:g.45547103A>C	gnomAD
NCI-TCGA novel	p.Gln455Glu	missense variant	-	NC_000006.12:g.45547102C>G	NCI-TCGA
rs1306807681	p.Phe456Leu	missense variant	-	NC_000006.12:g.45547105T>C	TOPMed
rs775121825	p.Phe456Leu	missense variant	-	NC_000006.12:g.45547107T>G	ExAC,gnomAD
rs932622541	p.Pro457Leu	missense variant	-	NC_000006.12:g.45547109C>T	TOPMed
rs746700872	p.Pro457Ser	missense variant	-	NC_000006.12:g.45547108C>T	ExAC,gnomAD
rs768473049	p.Pro460Leu	missense variant	-	NC_000006.12:g.45547118C>T	ExAC,TOPMed,gnomAD
RCV000784916	p.Pro460Leu	missense variant	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45547118C>T	ClinVar
NCI-TCGA novel	p.Pro460Ser	missense variant	-	NC_000006.12:g.45547117C>T	NCI-TCGA
RCV000784915	p.Pro460Leu	missense variant	Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB)	NC_000006.12:g.45547118C>T	ClinVar
rs554124503	p.Gly461Ala	missense variant	-	NC_000006.12:g.45547121G>C	1000Genomes,ExAC,gnomAD
rs765089321	p.Gly461Arg	missense variant	-	NC_000006.12:g.45547120G>C	ExAC,TOPMed,gnomAD
COSM214471	p.Gly462GluPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45547119G>-	NCI-TCGA Cosmic
VAR_079580	p.Gly462_Tyr521del	inframe_deletion	Cleidocranial dysplasia (CLCD) [MIM:119600]	-	UniProt
rs1378225599	p.Asp463Asn	missense variant	-	NC_000006.12:g.45547126G>A	gnomAD
rs148639759	p.Arg464Gln	missense variant	-	NC_000006.12:g.45547130G>A	ESP,ExAC,gnomAD
rs148639759	p.Arg464Leu	missense variant	-	NC_000006.12:g.45547130G>T	ESP,ExAC,gnomAD
rs373218126	p.Arg464Trp	missense variant	-	NC_000006.12:g.45547129C>T	ESP,ExAC,TOPMed,gnomAD
rs751811026	p.Pro466Ser	missense variant	-	NC_000006.12:g.45547135C>T	ExAC,TOPMed,gnomAD
rs142108189	p.Pro471Leu	missense variant	-	NC_000006.12:g.45547151C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1173869662	p.Pro472Leu	missense variant	-	NC_000006.12:g.45547154C>T	gnomAD
rs1319186519	p.Thr476Ile	missense variant	-	NC_000006.12:g.45547166C>T	TOPMed,gnomAD
rs1310470522	p.Thr476Ala	missense variant	-	NC_000006.12:g.45547165A>G	gnomAD
NCI-TCGA novel	p.Thr476Asn	missense variant	-	NC_000006.12:g.45547166C>A	NCI-TCGA
COSM1079825	p.Ser477Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45547169C>T	NCI-TCGA Cosmic
rs746611102	p.Gly479Val	missense variant	-	NC_000006.12:g.45547175G>T	ExAC,gnomAD
rs1215754855	p.Ser480Asn	missense variant	-	NC_000006.12:g.45547178G>A	gnomAD
rs780973109	p.Thr481Met	missense variant	-	NC_000006.12:g.45547181C>T	ExAC,TOPMed,gnomAD
rs768220317	p.Thr481Ala	missense variant	-	NC_000006.12:g.45547180A>G	ExAC,gnomAD
COSM1079827	p.Leu482AlaPheSerTerUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000006.12:g.45547181_45547182insG	NCI-TCGA Cosmic
rs1421970328	p.Pro485Thr	missense variant	-	NC_000006.12:g.45547192C>A	TOPMed,gnomAD
rs773277224	p.Pro485Gln	missense variant	-	NC_000006.12:g.45547193C>A	ExAC,gnomAD
rs1421970328	p.Pro485Ser	missense variant	-	NC_000006.12:g.45547192C>T	TOPMed,gnomAD
rs1041952480	p.Pro488Ser	missense variant	-	NC_000006.12:g.45547201C>T	TOPMed,gnomAD
rs1445706105	p.Gly493Ser	missense variant	-	NC_000006.12:g.45547216G>A	TOPMed
rs771087017	p.Asp495Asn	missense variant	-	NC_000006.12:g.45547222G>A	ExAC,TOPMed,gnomAD
rs774604105	p.Ala496Val	missense variant	-	NC_000006.12:g.45547226C>T	ExAC,gnomAD
rs759738332	p.Asp497Asn	missense variant	-	NC_000006.12:g.45547228G>A	ExAC,gnomAD
rs1322886581	p.Gly498Glu	missense variant	-	NC_000006.12:g.45547232G>A	gnomAD
rs1312686830	p.Gly498Arg	missense variant	-	NC_000006.12:g.45547231G>A	gnomAD
NCI-TCGA novel	p.Ser503Phe	missense variant	-	NC_000006.12:g.45547247C>T	NCI-TCGA
COSM1079829	p.Ser503Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000006.12:g.45547247C>A	NCI-TCGA Cosmic
rs753025447	p.Thr505Ala	missense variant	-	NC_000006.12:g.45547252A>G	ExAC,gnomAD
NCI-TCGA novel	p.Val506Phe	missense variant	-	NC_000006.12:g.45547255G>T	NCI-TCGA
rs1199568242	p.Leu507Met	missense variant	-	NC_000006.12:g.45547258T>A	gnomAD
NCI-TCGA novel	p.Ser509Tyr	missense variant	-	NC_000006.12:g.45547265C>A	NCI-TCGA
rs1401522703	p.Ser510Asn	missense variant	-	NC_000006.12:g.45547268G>A	TOPMed
rs11498198	p.Gly511Arg	missense variant	-	NC_000006.12:g.45547270G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs11498198	p.Gly511Ser	missense variant	-	NC_000006.12:g.45547270G>A	UniProt,dbSNP
VAR_012150	p.Gly511Ser	missense variant	-	NC_000006.12:g.45547270G>A	UniProt
rs11498198	p.Gly511Ser	missense variant	-	NC_000006.12:g.45547270G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs11498198	p.Gly511Cys	missense variant	-	NC_000006.12:g.45547270G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly511Asp	missense variant	-	NC_000006.12:g.45547271G>A	NCI-TCGA
RCV000506710	p.Gly511Ser	missense variant	-	NC_000006.12:g.45547270G>A	ClinVar
rs754318665	p.Met513Thr	missense variant	-	NC_000006.12:g.45547277T>C	ExAC,gnomAD
rs1256708103	p.Asp514Asn	missense variant	-	NC_000006.12:g.45547279G>A	gnomAD
NCI-TCGA novel	p.Asp514Gly	missense variant	-	NC_000006.12:g.45547280A>G	NCI-TCGA
NCI-TCGA novel	p.Asp514Glu	missense variant	-	NC_000006.12:g.45547281T>G	NCI-TCGA
NCI-TCGA novel	p.Val517Ala	missense variant	-	NC_000006.12:g.45547289T>C	NCI-TCGA
rs1362755731	p.Trp518Cys	missense variant	-	NC_000006.12:g.45547293G>T	TOPMed,gnomAD
rs1218682510	p.Arg519Gln	missense variant	-	NC_000006.12:g.45547295G>A	gnomAD
rs104893994	p.Ter522Ser	stop lost	-	NC_000006.12:g.45547304G>C	-
RCV000009889	p.Ter522Ser	stop lost	Cleidocranial dysostosis (CCD)	NC_000006.12:g.45547304G>C	ClinVar
NCI-TCGA novel	p.Ter522LeuGluUnkThrTerUnkUnk	stop lost	-	NC_000006.12:g.45547304G>T	NCI-TCGA

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000768	Congenital Abnormality	group	BEFREE
C0001418	Adenocarcinoma	group	BEFREE
C0002895	Anemia, Sickle Cell	disease	BEFREE
C0003130	Anoxia	phenotype	LHGDN
C0003507	Aortic Valve Stenosis	disease	BEFREE
C0003864	Arthritis	disease	BEFREE
C0003872	Arthritis, Psoriatic	disease	CTD_human
C0003873	Rheumatoid Arthritis	disease	CTD_human
C0005938	Bone Density	phenotype	GWASCAT
C0005940	Bone Diseases	group	BEFREE;LHGDN
C0005967	Bone neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007133	Carcinoma, Papillary	disease	BEFREE;LHGDN
C0008479	Chondrosarcoma	disease	BEFREE;LHGDN
C0008626	Congenital chromosomal disease	group	BEFREE
C0008925	Cleft Palate	disease	BEFREE
C0008928	Cleidocranial Dysplasia	disease	BEFREE;CLINVAR;CTD_human;LHGDN;MGD;ORPHANET;UNIPROT
C0009319	Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0010278	Craniosynostosis	disease	BEFREE;GENOMICS_ENGLAND
C0010308	Congenital Hypothyroidism	disease	MGD
C0011053	Deafness	phenotype	HPO
C0011334	Dental caries	disease	BEFREE;HPO
C0011351	Dental Enamel Hypoplasia	disease	HPO
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE
C0015230	Exanthema	phenotype	BEFREE
C0016063	Osteitis Fibrosa Disseminata	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018772	Hearing Loss, Partial	phenotype	HPO
C0018799	Heart Diseases	group	BEFREE
C0020456	Hyperglycemia	disease	BEFREE
C0020492	Hyperostosis	disease	BEFREE
C0020534	Orbital separation excessive	phenotype	HPO
C0022821	Kyphosis deformity of spine	phenotype	HPO
C0023418	leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023487	Acute Promyelocytic Leukemia	disease	BEFREE
C0024121	Lung Neoplasms	group	BEFREE
C0024299	Lymphoma	group	BEFREE
C0024591	Malignant hyperpyrexia due to anesthesia	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0024899	Mastocytosis	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0025990	Micrognathism	disease	HPO
C0026470	Monoclonal Gammopathy of Undetermined Significance	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE;LHGDN
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0027651	Neoplasms	group	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0028259	Nodule	phenotype	BEFREE
C0029396	Heterotopic Ossification	phenotype	LHGDN
C0029408	Degenerative polyarthritis	disease	BEFREE;CTD_human
C0029417	Osteoblastoma	disease	BEFREE
C0029422	Osteochondrodysplasias	group	BEFREE;HPO
C0029434	Osteogenesis Imperfecta	disease	GENOMICS_ENGLAND
C0029441	Osteoid osteoma	disease	BEFREE
C0029453	Osteopenia	disease	BEFREE
C0029456	Osteoporosis	disease	BEFREE;HPO;LHGDN
C0029463	Osteosarcoma	disease	BEFREE;CTD_human;LHGDN
C0029464	Osteosclerosis	disease	HPO
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030469	Paranasal Sinus Diseases	group	HPO
C0032019	Pituitary Neoplasms	group	BEFREE
C0032339	Rothmund-Thomson syndrome	disease	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE;LHGDN
C0033581	prostatitis	disease	BEFREE
C0035078	Kidney Failure	disease	BEFREE
C0035335	Retinoblastoma	disease	BEFREE
C0035372	Rett Syndrome	disease	BEFREE
C0036439	Scoliosis, unspecified	phenotype	BEFREE
C0037199	Sinusitis	disease	HPO
C0037932	Curvature of spine	phenotype	HPO
C0038016	Spondylolisthesis	phenotype	HPO
C0038018	Spondylolysis	disease	HPO
C0039144	Syringomyelia	disease	HPO
C0040136	Thyroid Neoplasm	disease	BEFREE
C0040427	Tooth Abnormalities	group	CTD_human
C0040457	Tooth, Supernumerary	phenotype	HPO
C0041948	Uremia	disease	BEFREE;CTD_human
C0042769	Virus Diseases	group	BEFREE
C0080174	Spina Bifida Occulta	disease	HPO
C0086743	Osteoarthrosis Deformans	disease	CTD_human
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152244	Bone Cysts, Aneurysmal	disease	BEFREE
C0153690	Secondary malignant neoplasm of bone	disease	BEFREE
C0158779	Cervical rib	disease	HPO
C0175699	Saethre-Chotzen Syndrome	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0205647	Follicular adenoma	disease	BEFREE
C0206638	Giant Cell Tumor of Bone	disease	BEFREE
C0206640	Ossifying Fibroma	disease	BEFREE
C0220620	Gastrointestinal Carcinoid Tumor	disease	BEFREE
C0220658	Pfeiffer Syndrome	disease	BEFREE
C0221354	Frontal bossing	disease	HPO
C0221357	Brachydactyly	disease	HPO
C0232513	Premature tooth loss	phenotype	HPO
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0239138	Hip joint varus deformity - observation	phenotype	HPO
C0239174	Late tooth eruption	phenotype	HPO
C0240310	Hypoplasia of the maxilla	disease	HPO
C0240538	Convex nasal ridge	phenotype	HPO
C0240635	Byzanthine arch palate	disease	HPO
C0243057	Stomatognathic System Abnormalities	group	CTD_human
C0259779	Fibrous Dysplasia	disease	BEFREE
C0263661	Disorder of skeletal system	group	BEFREE
C0265294	Pyle metaphyseal dysplasia	disease	HPO
C0266061	Open Bite	phenotype	HPO
C0271441	Chronic otitis media	disease	HPO
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0279530	Malignant Bone Neoplasm	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0302501	Mandibular hyperplasia	phenotype	HPO
C0333519	Caries (morphologic abnormality)	disease	BEFREE
C0334041	Osteoma cutis	disease	BEFREE
C0339789	Congenital deafness	disease	HPO
C0342200	Endemic Cretinism	disease	MGD
C0345904	Malignant neoplasm of liver	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0346957	Disseminated Malignant Neoplasm	phenotype	BEFREE
C0349588	Short stature	phenotype	HPO
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0376634	Craniofacial Abnormalities	group	BEFREE;CTD_human
C0399385	Early tooth exfoliation	disease	HPO
C0399526	Class III malocclusion	disease	HPO
C0410528	Skeletal dysplasia	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0426790	Narrow thorax	phenotype	HPO
C0426799	Congenital hypoplasia of clavicle	disease	BEFREE;HPO
C0426817	Short ribs	phenotype	HPO
C0432073	Defect of skull ossification	group	HPO
C0456132	Large fontanelle	phenotype	HPO
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0524730	Odontome	disease	CTD_human
C0549473	Thyroid carcinoma	disease	BEFREE
C0578038	Thin lips	phenotype	HPO
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0686761	Lack of bone formation	phenotype	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0700208	Acquired scoliosis	phenotype	BEFREE;HPO
C0740421	Postsurgical menopause	disease	BEFREE
C0740749	Chronic metabolic acidosis	disease	BEFREE
C0743359	Chronic ear infection	disease	HPO
C0751606	Adult Acute Lymphocytic Leukemia	disease	BEFREE
C0751951	Central Core Myopathy (disorder)	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0858252	Breast adenocarcinoma	disease	BEFREE
C0862878	Dedifferentiated chondrosarcoma	disease	BEFREE
C0936223	Metastatic Prostate Carcinoma	disease	BEFREE
C0936248	Chondroma	disease	LHGDN
C0949690	Spondylarthritis	disease	CTD_human
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1145670	Respiratory Failure	disease	BEFREE
C1260873	Aortic valve disorder	group	BEFREE
C1282496	Metastasis from malignant tumor of prostate	disease	BEFREE
C1301034	Pancreatic intraepithelial neoplasia	disease	BEFREE
C1306459	Primary malignant neoplasm	group	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1332986	Childhood Osteosarcoma	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1335473	Primary chondrosarcoma of bone	disease	BEFREE
C1384666	hearing impairment	phenotype	HPO
C1390474	Increased susceptibility to fractures	phenotype	HPO
C1398312	Narrow palate	phenotype	HPO
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1511789	Desmoplastic	disease	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1654637	androgen independent prostate cancer	disease	BEFREE
C1834060	Short middle phalanx of the 5th finger	phenotype	HPO
C1834969	Metaphyseal Dysplasia with Maxillary Hypoplasia and Brachydactyly	disease	BEFREE;CTD_human
C1836184	Short femoral neck	phenotype	HPO
C1836542	Depressed nasal bridge	phenotype	HPO
C1837078	Hypoplastic inferior ilia	phenotype	HPO
C1837404	High, narrow palate	phenotype	HPO
C1838416	CLEIDOCRANIAL DYSPLASIA, FORME FRUSTE, DENTAL ANOMALIES ONLY	disease	CLINVAR;UNIPROT
C1842083	Abnormality of the ribs	phenotype	HPO
C1844508	Large foramen magnum	phenotype	HPO
C1844704	Platyspondyly	phenotype	HPO
C1845112	Hyperkyphosis	phenotype	HPO
C1846434	Hypoplastic scapulae	phenotype	HPO
C1849537	Persistent open anterior fontanelle	phenotype	HPO
C1849538	Delayed eruption of primary teeth	phenotype	HPO
C1849540	Delayed eruption of permanent teeth	phenotype	HPO
C1850135	Flared metaphysis	phenotype	HPO
C1851854	Thin dental enamel	phenotype	HPO
C1853195	Prostate Cancer, Hereditary, 7	disease	BEFREE
C1853242	Midface retrusion	phenotype	HPO
C1855669	Absent frontal sinuses	phenotype	HPO
C1856872	Down-sloping shoulders	phenotype	HPO
C1857126	Parietal bossing	phenotype	HPO
C1857130	Hypoplastic mandible condyle	phenotype	HPO
C1857131	Absent paranasal sinuses	phenotype	HPO
C1857190	Wide pubic symphysis	phenotype	HPO
C1857665	Aplastic clavicles	phenotype	HPO
C1857679	Sloping forehead	phenotype	HPO
C1858085	Malar flattening	phenotype	HPO
C1858452	Thickened calvaria	phenotype	HPO
C1859480	Cone-shaped epiphyses of the phalanges of the hand	phenotype	HPO
C1859682	Hypoplastic frontal sinuses	phenotype	HPO
C1861324	Short philtrum	phenotype	HPO
C1861388	Short 5th metacarpal	phenotype	HPO
C1861516	Cleidocranial Dysplasia, Forme Fruste, With Brachydactyly	disease	CLINVAR;UNIPROT
C1861517	Abnormal facility in opposing the shoulders	phenotype	HPO
C1861519	Moderately short stature	phenotype	HPO
C1861528	Delayed mineralization of pubic bone	phenotype	HPO
C1861531	Long second metacarpal	phenotype	HPO
C1861923	Acampomelic Campomelic Dysplasia	disease	BEFREE
C1862140	Brachydactyly type A3	disease	HPO
C1865027	Hypoplastic iliac wing	phenotype	HPO
C1866710	Delayed pubic bone ossification	phenotype	HPO
C1961099	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	disease	BEFREE
C2227134	mandibular excess (physical finding)	phenotype	HPO
C2239176	Liver carcinoma	disease	BEFREE
C2673410	Small midface	phenotype	HPO
C2699510	Split-Hand/Foot Malformation	disease	BEFREE
C2936258	Peri-Implantitis	disease	BEFREE
C2981150	Uranostaphyloschisis	disease	BEFREE;HPO
C3463824	MYELODYSPLASTIC SYNDROME	group	BEFREE
C3549874	METAPHYSEAL DYSPLASIA WITH MAXILLARY HYPOPLASIA WITH OR WITHOUT BRACHYDACTYLY	disease	BEFREE;ORPHANET
C3550546	Depressed nasal root/bridge	phenotype	HPO
C3714756	Intellectual Disability	group	GENOMICS_ENGLAND
C3714948	PACHYONYCHIA CONGENITA 3	disease	BEFREE
C3804986	Aplasia of paranasal sinuses	disease	HPO
C3806482	Recurrent respiratory infections	phenotype	HPO
C3888088	SMITH-MCCORT DYSPLASIA 1	disease	BEFREE
C4016655	CLEIDOCRANIAL DYSPLASIA, SEVERE, WITH OSTEOPOROSIS AND SCOLIOSIS	phenotype	CLINVAR
C4021242	Hypoplasia of the zygomatic bone	phenotype	HPO
C4021435	Short middle phalanx of the 2nd finger	phenotype	HPO
C4021785	Abnormality of the metacarpal bones	phenotype	HPO
C4021790	Abnormality of the skeletal system	phenotype	BEFREE
C4021800	Abnormality of dental enamel	phenotype	HPO
C4023457	Short face	phenotype	HPO
C4024589	Aplasia/Hypoplasia of the mandible	phenotype	HPO
C4025119	Multiple small vertebral fractures	phenotype	HPO
C4025170	Osteoporosis of vertebrae	disease	HPO
C4025250	Abnormality of the sacrum	phenotype	HPO
C4072820	Large bregma sutures	phenotype	HPO
C4072821	Large, late-closing fontanelle	phenotype	HPO
C4072822	Wide bregma sutures	phenotype	HPO
C4072844	Missing sinuses	phenotype	HPO
C4072879	Small cheekbone	phenotype	HPO
C4073291	Hyperplasia of foramen magnum	phenotype	HPO
C4082243	Maxillary retrognathia	phenotype	HPO
C4280262	Dystrophic tooth enamel	phenotype	HPO
C4280320	Hypotrophic midface	phenotype	HPO
C4280321	Decreased projection of midface	phenotype	HPO
C4280368	Hypotrophic cheekbone	phenotype	HPO
C4280369	Flattening of the zygomatic bone	phenotype	HPO
C4280370	Depressed cheekbone	phenotype	HPO
C4280411	Delayed maturation fo pubic bone	phenotype	HPO
C4280456	Dysplasia of tooth enamel	phenotype	HPO
C4280457	Defective enamel matrix	phenotype	HPO
C4280495	Concave bridge of nose	phenotype	HPO
C4280533	Decreased calcification of skull	phenotype	HPO
C4280548	Hypotrophic frontal sinus	phenotype	HPO
C4280549	Decreased pneumatization of frontal sinus	phenotype	HPO
C4280554	Increased diameter of foramen magnum	phenotype	HPO
C4280555	Increased circumference of foramen magnum	phenotype	HPO
C4280559	Aplasia of frontal sinus	phenotype	HPO
C4280560	Increased thickness of cranium	phenotype	HPO
C4280567	Abnormal skeletal development	phenotype	HPO
C4280615	Defective tooth enamel	phenotype	HPO
C4280623	Rotting teeth	phenotype	HPO
C4280640	Retrusion of upper jaw bones	phenotype	HPO
C4280641	Hypotrophic maxilla	phenotype	HPO
C4280642	Deficiency of upper jaw bones	phenotype	HPO
C4280643	Decreased projection of maxilla	phenotype	HPO
C4280644	Increased size of the mandible	phenotype	HPO
C4280645	Hypertrophy of lower jaw	phenotype	HPO
C4280651	Hypotrophic malar bone	phenotype	HPO
C4281993	Neonatal respiratory distress	phenotype	HPO
C4282132	Malignancy	phenotype	BEFREE
C4317152	Dimple chin	phenotype	HPO
C4476523	Decreased projection of lower jaw	phenotype	HPO
C4476524	Decreased projection of mandible	phenotype	HPO
C4476525	Retrusion of lower jaw	phenotype	HPO
C4520898	Stage IV Breast Cancer AJCC v6 and v7	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000978	RNA polymerase II cis-regulatory region sequence-specific DNA binding	IEA
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISA
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISM
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	IBA
GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	IEA
GO:0003682	chromatin binding	IEA
GO:0003700	DNA-binding transcription factor activity	NAS
GO:0005515	protein binding	IPI
GO:0005524	ATP binding	IEA
GO:0019904	protein domain specific binding	IEA
GO:0043425	bHLH transcription factor binding	IEA
GO:0070491	repressing transcription factor binding	IEA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0001503	ossification	TAS
GO:0001503	ossification	IBA
GO:0001649	osteoblast differentiation	TAS
GO:0001649	osteoblast differentiation	IEP
GO:0001958	endochondral ossification	IEA
GO:0002051	osteoblast fate commitment	IEA
GO:0002062	chondrocyte differentiation	IBA
GO:0002063	chondrocyte development	IEA
GO:0002076	osteoblast development	IEA
GO:0006357	regulation of transcription by RNA polymerase II	IBA
GO:0006367	transcription initiation from RNA polymerase II promoter	TAS
GO:0008284	positive regulation of cell population proliferation	IEA
GO:0030097	hemopoiesis	IBA
GO:0030182	neuron differentiation	IBA
GO:0030217	T cell differentiation	IEA
GO:0030509	BMP signaling pathway	ISS
GO:0032332	positive regulation of chondrocyte differentiation	IEA
GO:0035115	embryonic forelimb morphogenesis	IEA
GO:0040036	regulation of fibroblast growth factor receptor signaling pathway	IEA
GO:0042475	odontogenesis of dentin-containing tooth	IEA
GO:0042487	regulation of odontogenesis of dentin-containing tooth	IEA
GO:0045595	regulation of cell differentiation	IBA
GO:0045669	positive regulation of osteoblast differentiation	IMP
GO:0045879	negative regulation of smoothened signaling pathway	IEA
GO:0045892	negative regulation of transcription, DNA-templated	IDA
GO:0045893	positive regulation of transcription, DNA-templated	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	IMP
GO:0048469	cell maturation	IEA
GO:0048701	embryonic cranial skeleton morphogenesis	IEA
GO:0048863	stem cell differentiation	IEA
GO:0071773	cellular response to BMP stimulus	ISS
GO:1901522	positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus	ISS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000790	nuclear chromatin	ISS
GO:0000790	nuclear chromatin	ISA
GO:0005634	nucleus	IBA
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	IDA
GO:0005654	nucleoplasm	TAS
GO:0005667	transcription factor complex	IEA
GO:0005829	cytosol	TAS

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	IEA
R-HSA-212436	Generic Transcription Pathway	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-73857	RNA Polymerase II Transcription	IEA
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	IEA
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8878166	Transcriptional regulation by RUNX2	IEA
R-HSA-8878166	Transcriptional regulation by RUNX2	TAS
R-HSA-8878171	Transcriptional regulation by RUNX1	TAS
R-HSA-8939246	RUNX1 regulates transcription of genes involved in differentiation of myeloid cells	TAS
R-HSA-8939902	Regulation of RUNX2 expression and activity	IEA
R-HSA-8939902	Regulation of RUNX2 expression and activity	TAS
R-HSA-8940973	RUNX2 regulates osteoblast differentiation	IEA
R-HSA-8940973	RUNX2 regulates osteoblast differentiation	TAS
R-HSA-8941284	RUNX2 regulates chondrocyte maturation	IEA
R-HSA-8941326	RUNX2 regulates bone development	IEA
R-HSA-8941326	RUNX2 regulates bone development	TAS
R-HSA-8941332	RUNX2 regulates genes involved in cell migration	TAS
R-HSA-8941332	RUNX2 regulates genes involved in cell migration	IEA
R-HSA-8941333	RUNX2 regulates genes involved in differentiation of myeloid cells	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C097240	15-deoxy-delta(12,14)-prostaglandin J2	15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA	12021203
C119129	18alpha-glycyrrhetinic acid	18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]	21910061
C119129	18alpha-glycyrrhetinic acid	18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]	21910061
C119129	18alpha-glycyrrhetinic acid	18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]	21910061
D015632	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RUNX2 mRNA	30529163
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of RUNX2 mRNA	20453058
C029790	2,2',3',4,4',5-hexachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
C029790	2,2',3',4,4',5-hexachlorobiphenyl	2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of RUNX2 mRNA	23829299
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of RUNX2 mRNA]	17689939
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of RUNX2 mRNA	17689939
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in decreased expression of RUNX2]	24531206
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26053266; 26136938;
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26136938
C019273	2,2-bis(4-glycidyloxyphenyl)propane	2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	30481989
C081766	2,4,4'-trichlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
C009828	2,4,5,2',5'-pentachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
C009407	2,5,2',5'-tetrachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA]	23625689
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased expression of RUNX2 mRNA	23625689
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26053266
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]	20458730
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C550547	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased expression of RUNX2 mRNA	29653943
C550547	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	DDIT3 protein affects the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased expression of RUNX2 mRNA]	29653943
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of RUNX2 mRNA	20382639
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of RUNX2 mRNA	19150397
C496492	abrine	abrine results in increased expression of RUNX2 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of RUNX2 mRNA	29067470
C056165	acetovanillone	acetovanillone inhibits the reaction [Palmitic Acid results in increased expression of RUNX2 mRNA]	24080574
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Cadmium Chloride results in decreased expression of RUNX2 mRNA]	19017541
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Dexamethasone affects the expression of RUNX2 mRNA]	24239970
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of RUNX2 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of RUNX2 intron	30157460
D019386	Alendronate	Alendronate promotes the reaction [Modafinil results in increased expression of RUNX2 mRNA]	29649498
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin results in decreased expression of RUNX2 mRNA	28522335
D000077410	Aluminum Chloride	[Sodium Fluoride co-treated with Aluminum Chloride] results in increased expression of RUNX2 mRNA	21560300
D000077410	Aluminum Chloride	Aluminum Chloride results in decreased expression of RUNX2 mRNA	27470910
D000077410	Aluminum Chloride	ginsenoside Rb1 inhibits the reaction [Aluminum Chloride results in decreased expression of RUNX2 mRNA]	27470910
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of RUNX2 mRNA	16483693
C088115	anacardic acid	anacardic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA]	24819975
D001151	Arsenic	Arsenic affects the methylation of RUNX2 gene	25304211
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of RUNX2 mRNA	20458559
D000077237	Arsenic Trioxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in decreased expression of RUNX2]	24531206
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of RUNX2	24531206
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of RUNX2 mRNA	22465848
C015001	arsenite	arsenite results in increased methylation of RUNX2 promoter	23974009
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of RUNX2 mRNA	18687144
D001205	Ascorbic Acid	[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	26424790
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of RUNX2 mRNA	28105418
D001205	Ascorbic Acid	[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA	17692823
D001205	Ascorbic Acid	EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	26424790
D001205	Ascorbic Acid	[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA	26492236
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of RUNX2 mRNA	20530736
D001205	Ascorbic Acid	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]	26492236
D001205	Ascorbic Acid	U 0126 inhibits the reaction [Ascorbic Acid results in increased expression of RUNX2 mRNA]	20530736
D001205	Ascorbic Acid	[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein	27387537
D001205	Ascorbic Acid	[Ascorbic Acid co-treated with Phosphates] results in increased expression of RUNX2 mRNA	21613385
D001205	Ascorbic Acid	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA	27028516
D001205	Ascorbic Acid	Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]	27387537
D001205	Ascorbic Acid	ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]	27387537
D001205	Ascorbic Acid	Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]	27028516
D001205	Ascorbic Acid	NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]	27387537
D001205	Ascorbic Acid	Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]	27028516
D001205	Ascorbic Acid	2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	30481989
D001205	Ascorbic Acid	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	30481989
D001205	Ascorbic Acid	[Ascorbic Acid co-treated with IL11 protein] results in increased expression of RUNX2 mRNA	17956465
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of RUNX2 mRNA	17274723
C547126	AZM551248	AZM551248 results in increased expression of RUNX2 mRNA	22323515
D001554	Benzene	Benzene results in increased expression of RUNX2 mRNA	22960397
D001554	Benzene	Benzene results in decreased expression of RUNX2 mRNA	15120971
D001599	Berberine	Berberine results in increased expression of RUNX2 mRNA	26478571
D001599	Berberine	CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]	26478571
D001599	Berberine	DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]	26478571
C031463	beta-glycerophosphoric acid	[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	26424790
C031463	beta-glycerophosphoric acid	[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA	17692823
C031463	beta-glycerophosphoric acid	EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	26424790
C031463	beta-glycerophosphoric acid	[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA	26492236
C031463	beta-glycerophosphoric acid	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]	26492236
C031463	beta-glycerophosphoric acid	[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein	27387537
C031463	beta-glycerophosphoric acid	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA	27028516
C031463	beta-glycerophosphoric acid	Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]	27387537
C031463	beta-glycerophosphoric acid	ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]	27387537
C031463	beta-glycerophosphoric acid	Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]	27028516
C031463	beta-glycerophosphoric acid	NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]	27387537
C031463	beta-glycerophosphoric acid	Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]	27028516
C031463	beta-glycerophosphoric acid	2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	30481989
C031463	beta-glycerophosphoric acid	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	30481989
D001629	Bezafibrate	Bezafibrate results in increased expression of RUNX2 mRNA	21499286
D001629	Bezafibrate	dorsomorphin inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA]	21499286
D001629	Bezafibrate	GSK0660 inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA]	21499286
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of RUNX2 mRNA	30951980
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
C006780	bisphenol A	bisphenol A results in decreased expression of RUNX2 mRNA	30075455
C006780	bisphenol A	bisphenol A affects the methylation of RUNX2 promoter	27334623
C006780	bisphenol A	bisphenol A results in decreased expression of RUNX2 mRNA	23900028
C006780	bisphenol A	bisphenol A results in increased expression of RUNX2 mRNA	30951980
C006780	bisphenol A	bisphenol A results in decreased expression of RUNX2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased expression of RUNX2 mRNA	30816183
C006780	bisphenol A	bisphenol A results in increased methylation of RUNX2 gene	28505145
C000611646	bisphenol F	bisphenol F results in increased expression of RUNX2 mRNA	30951980
C032688	boric acid	boric acid affects the expression of RUNX2 mRNA	24704097
D000069286	Bortezomib	Bortezomib results in increased expression of RUNX2 protein	19894220
C038091	butylparaben	butylparaben results in decreased expression of RUNX2 mRNA	28527915
D002104	Cadmium	Cadmium results in decreased expression of RUNX2 mRNA	20570719
D019256	Cadmium Chloride	Acetylcysteine inhibits the reaction [Cadmium Chloride results in decreased expression of RUNX2 mRNA]	19017541
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of RUNX2	22019892
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of RUNX2 mRNA	19017541; 25596134;
C055494	caffeic acid phenethyl ester	caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	28363435
D002110	Caffeine	Caffeine results in decreased expression of RUNX2 mRNA	30423288
D002112	Calcifediol	Calcifediol results in increased expression of RUNX2 mRNA	21542014
D002112	Calcifediol	CYP27B1 protein promotes the reaction [Calcifediol results in increased expression of RUNX2 mRNA]	21542014
D002112	Calcifediol	Ketoconazole inhibits the reaction [Calcifediol results in increased expression of RUNX2 mRNA]	21542014
D002117	Calcitriol	Calcitriol promotes the reaction [VDR protein binds to RUNX2 enhancer]	17293108
D002117	Calcitriol	Calcitriol results in decreased expression of RUNX2 mRNA	16002434; 26485663;
D002117	Calcitriol	Calcitriol results in increased expression of RUNX2 mRNA	21542014; 28105418;
D002117	Calcitriol	Calcitriol results in decreased expression of RUNX2 mRNA	17293108
D002117	Calcitriol	Calcitriol results in increased expression of RUNX2 protein	19092814
C058819	calphostin C	calphostin C inhibits the reaction [FGF2 protein results in increased expression of and results in increased activity of RUNX2 protein]	12403780
C058819	calphostin C	calphostin C inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
D002164	Camphor	Camphor analog affects the expression of RUNX2 mRNA	24704097
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of RUNX2 mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of RUNX2 mRNA	17334410
D002251	Carbon Tetrachloride	FR 167653 inhibits the reaction [Carbon Tetrachloride results in increased expression of RUNX2 mRNA]	17334410
D000068579	Celecoxib	[Celecoxib results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA	27050768
D000068579	Celecoxib	[Celecoxib results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein	27050768
D048271	Chitosan	Chitosan results in increased expression of RUNX2 mRNA	25246786
D048271	Chitosan	Chitosan results in increased expression of RUNX2 protein	25246786
C004656	chloroacetaldehyde	chloroacetaldehyde results in decreased expression of RUNX2 mRNA	25596134
D004390	Chlorpyrifos	[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of RUNX2 mRNA	27905518
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of RUNX2 mRNA	27905518
D002762	Cholecalciferol	[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA	17692823
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RUNX2 mRNA	20938992
C022990	chromic chloride	[cobaltous chloride co-treated with chromic chloride] affects the expression of RUNX2 mRNA	25966675
D002858	Chromium Alloys	Chromium Alloys results in decreased expression of RUNX2 mRNA	25966675
D000077404	Cidofovir	Cidofovir results in increased expression of RUNX2 mRNA	25596134
D002945	Cisplatin	Cisplatin affects the expression of RUNX2 mRNA	25596134
D002945	Cisplatin	Cisplatin promotes the reaction [jinfukang results in decreased expression of RUNX2 mRNA]	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of RUNX2 mRNA	27392435
D002945	Cisplatin	jinfukang promotes the reaction [Cisplatin results in decreased expression of RUNX2 mRNA]	27392435
D004002	Clodronic Acid	Clodronic Acid results in increased expression of RUNX2 mRNA	25596134
C007095	cobaltiprotoporphyrin	[cobaltiprotoporphyrin co-treated with IL1B protein] results in increased expression of RUNX2 mRNA	22155307
C018021	cobaltous chloride	cobaltous chloride affects the expression of RUNX2 mRNA	25966675
C018021	cobaltous chloride	[cobaltous chloride co-treated with chromic chloride] affects the expression of RUNX2 mRNA	25966675
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of RUNX2 mRNA	16772336
D003042	Cocaine	[Cocaine co-treated with Cocaine deficiency] promotes the reaction [RUNX2 protein binds to DNM1L promoter]	30158054
D003042	Cocaine	[Cocaine co-treated with Cocaine deficiency] promotes the reaction [RUNX2 protein binds to EGR3 promoter]	30158054
D003042	Cocaine	[Cocaine co-treated with Cocaine deficiency] promotes the reaction [RUNX2 protein binds to SMARCA4 promoter]	30158054
D003042	Cocaine	[Cocaine co-treated with Cocaine deficiency] results in increased expression of and results in increased activity of RUNX2 protein	30158054
D005576	Colforsin	Colforsin results in increased expression of RUNX2 mRNA	20197312
D003300	Copper	[Copper co-treated with Dietary Sucrose] results in increased expression of RUNX2 mRNA	26033743
D003300	Copper	Copper deficiency results in increased expression of RUNX2 mRNA	26033743
D003345	Corticosterone	Corticosterone results in decreased expression of RUNX2 mRNA	30423288
D003345	Corticosterone	Enalapril inhibits the reaction [Corticosterone results in decreased expression of RUNX2 mRNA]	30423288
D065366	Cryptoxanthins	[Cryptoxanthins co-treated with Vitamin A] results in increased expression of RUNX2 mRNA	15962303
D065366	Cryptoxanthins	Cryptoxanthins results in increased expression of RUNX2 mRNA	15962303
D065366	Cryptoxanthins	Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]	15962303
D065366	Cryptoxanthins	Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]	15962303
D003474	Curcumin	Curcumin results in decreased expression of RUNX2 protein	15129424
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]	15962303
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]	18327666
D003634	DDT	DDT results in increased expression of RUNX2 mRNA	25014179
D003676	Deferoxamine	Deferoxamine results in decreased expression of RUNX2 mRNA	16772336
D003907	Dexamethasone	Dexamethasone results in increased expression of RUNX2 mRNA	25286332; 26468166;
D003907	Dexamethasone	[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	26424790
D003907	Dexamethasone	Dexamethasone results in decreased expression of RUNX2 mRNA	25047013
D003907	Dexamethasone	EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	26424790
D003907	Dexamethasone	[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA	26492236
D003907	Dexamethasone	Dexamethasone results in decreased expression of RUNX2 protein	30878453
D003907	Dexamethasone	naringin inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	30878453
D003907	Dexamethasone	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]	26492236
D003907	Dexamethasone	Acetylcysteine inhibits the reaction [Dexamethasone affects the expression of RUNX2 mRNA]	24239970
D003907	Dexamethasone	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA	27028516
D003907	Dexamethasone	caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	28363435
D003907	Dexamethasone	Dexamethasone affects the expression of RUNX2 mRNA	24239970
D003907	Dexamethasone	Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]	27387537
D003907	Dexamethasone	Dexamethasone results in decreased expression of RUNX2 mRNA	27387537
D003907	Dexamethasone	Dexamethasone results in decreased expression of RUNX2 protein	27387537; 28363435;
D003907	Dexamethasone	ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]	27387537
D003907	Dexamethasone	ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]	27387537
D003907	Dexamethasone	ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	27387537
D003907	Dexamethasone	Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]	27028516
D003907	Dexamethasone	NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]	27387537
D003907	Dexamethasone	Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]	27028516
D003907	Dexamethasone	2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]	30481989
D003907	Dexamethasone	[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA	30481989
D004004	Dichlororibofuranosylbenzimidazole	Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]	15962303
D004004	Dichlororibofuranosylbenzimidazole	Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]	18327666
D004008	Diclofenac	Diclofenac results in increased expression of RUNX2 mRNA	30723492
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of RUNX2 mRNA	26924002
D019422	Dietary Sucrose	[Copper co-treated with Dietary Sucrose] results in increased expression of RUNX2 mRNA	26033743
D019422	Dietary Sucrose	Dietary Sucrose results in increased expression of RUNX2 mRNA	26033743
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of RUNX2 mRNA	31163220
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of RUNX2 mRNA	29945229
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of RUNX2 protein	22985736
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of RUNX2 mRNA	24535843
D004052	Diethylnitrosamine	[indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of RUNX2 mRNA	22129741
D004075	Diglycerides	Diglycerides results in increased expression of RUNX2 mRNA	22286232
C024629	dimethyl phthalate	dimethyl phthalate affects the expression of RUNX2 mRNA	26924002
D015237	Dinoprost	Dinoprost results in increased expression of RUNX2 mRNA	27050768
D015237	Dinoprost	Dinoprost results in increased expression of RUNX2 protein	27050768
D015232	Dinoprostone	Dinoprostone results in increased expression of RUNX2 mRNA	27050768
D015232	Dinoprostone	Dinoprostone results in increased expression of RUNX2 protein	27050768
D004221	Disulfiram	Disulfiram results in increased expression of RUNX2 mRNA	24496638
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
C516138	dorsomorphin	dorsomorphin inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA]	21499286
D004365	Drugs, Chinese Herbal	Drugs, Chinese Herbal results in increased expression of RUNX2 mRNA	16543677
D015118	Eicosapentaenoic Acid	Eicosapentaenoic Acid results in decreased expression of RUNX2 mRNA	21193197
D004656	Enalapril	Enalapril inhibits the reaction [Corticosterone results in decreased expression of RUNX2 mRNA]	30423288
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUNX2 mRNA	22079256
D004958	Estradiol	EGF protein promotes the reaction [Estradiol results in increased expression of RUNX2 mRNA]	24758408
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of RUNX2 mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of RUNX2 mRNA	30165855
D004958	Estradiol	Estradiol results in increased expression of RUNX2 mRNA	16202921; 17689939; 24758408;
D004958	Estradiol	Fulvestrant inhibits the reaction [Estradiol results in increased expression of RUNX2 mRNA]	17689939
D004958	Estradiol	Estradiol affects the expression of RUNX2 mRNA	17166402
D004967	Estrogens	Estrogens results in increased expression of RUNX2 mRNA	25014179
D004967	Estrogens	Estrogens affects the expression of RUNX2 mRNA	24098073
D000431	Ethanol	[Genistein co-treated with Ethanol] results in increased expression of RUNX2 mRNA	24872432
D000431	Ethanol	[Genistein co-treated with Ethanol] results in increased expression of RUNX2 protein	24872432
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of RUNX2 mRNA	23129252
C034096	ethoxyacetic acid	ethoxyacetic acid affects the expression of RUNX2 mRNA	24704097
D005031	Ethylenethiourea	[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of RUNX2 mRNA	27905518
C004808	farnesyl pyrophosphate	farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]	18310456
D005419	Flavonoids	Flavonoids results in increased expression of RUNX2 mRNA	16543677; 23238999;
D005459	Fluorides	Fluorides results in increased expression of RUNX2 mRNA	20709135
D005459	Fluorides	Fluorides inhibits the reaction [potassium phosphate results in increased expression of RUNX2 mRNA]	24561004
D005472	Fluorouracil	Fluorouracil affects the expression of RUNX2 mRNA	24704097
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RUNX2 mRNA	20938992
C104334	FR 167653	FR 167653 inhibits the reaction [Carbon Tetrachloride results in increased expression of RUNX2 mRNA]	17334410
C069837	fullerene C60	fullerene C60 results in increased expression of RUNX2 mRNA	19167457
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Estradiol results in increased expression of RUNX2 mRNA]	17689939
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA]	26362186
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Resveratrol results in increased expression of RUNX2 mRNA]	17689939
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [naringin results in increased expression of RUNX2 mRNA]	23596885
C057580	gallocatechol	gallocatechol results in increased expression of RUNX2 mRNA	21877759
D005680	gamma-Aminobutyric Acid	gamma-Aminobutyric Acid affects the expression of RUNX2 mRNA	24098073
C013172	gamma-oryzanol	gamma-oryzanol affects the expression of RUNX2 mRNA	24098073
D019833	Genistein	Genistein affects the expression of RUNX2 mRNA	17166402
D019833	Genistein	[Genistein co-treated with Ethanol] results in increased expression of RUNX2 mRNA	24872432
D019833	Genistein	[Genistein co-treated with Ethanol] results in increased expression of RUNX2 protein	24872432
D019833	Genistein	Genistein results in increased expression of RUNX2 mRNA	24872432
D019833	Genistein	Genistein results in increased expression of RUNX2 protein	24872432
D019833	Genistein	Genistein results in increased expression of RUNX2 mRNA	21877759
C002963	geranylgeranyl pyrophosphate	geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]	18310456
C112485	ginkgolic acid	ginkgolic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA]	24819975
C442759	ginsenoside Rb1	ginsenoside Rb1 inhibits the reaction [Aluminum Chloride results in decreased expression of RUNX2 mRNA]	27470910
C442759	ginsenoside Rb1	ginsenoside Rb1 results in increased expression of RUNX2 mRNA	27470910
C097367	ginsenoside Rg3	ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]	27387537
C097367	ginsenoside Rg3	ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]	27387537
C097367	ginsenoside Rg3	ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	27387537
C097367	ginsenoside Rg3	NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]	27387537
D005944	Glucosamine	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]	20458730
D005944	Glucosamine	Glucosamine analog results in increased expression of RUNX2 mRNA	20458730
D005944	Glucosamine	Glucosamine analog results in increased phosphorylation of RUNX2 protein	20458730
D005947	Glucose	[EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA	30894315
D005947	Glucose	[EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein	30894315
D005947	Glucose	Glucose results in increased expression of RUNX2 mRNA	17178593
D005960	Glucosides	Glucosides analog affects the expression of RUNX2 mRNA	24098073
C004312	glycidol	glycidol results in increased expression of RUNX2 mRNA	24915197
C529769	GSK0660	GSK0660 inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA]	21499286
C577920	GSK126	GSK126 results in increased expression of RUNX2 mRNA	26424790
C047845	heraclenin	heraclenin results in increased expression of RUNX2 mRNA	31319076
C409722	hexaconazole	hexaconazole affects the expression of RUNX2 mRNA	24704097
D006851	Hydrochloric Acid	Hydrochloric Acid results in increased expression of RUNX2 mRNA	17183249
D006851	Hydrochloric Acid	Hydrochloric Acid results in increased expression of RUNX2 protein	17183249
D006861	Hydrogen Peroxide	DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]]	26482937
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased expression of RUNX2 mRNA	26482937
D006861	Hydrogen Peroxide	naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]	26482937
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]	27028516
D006861	Hydrogen Peroxide	Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]	27028516
C031927	hydroquinone	hydroquinone results in increased expression of RUNX2 mRNA	22960397
D006918	Hydroxyurea	Hydroxyurea affects the expression of RUNX2 mRNA	24704097
C056599	icariin	icariin results in increased expression of RUNX2 mRNA	18295595; 19747809;
C056599	icariin	NOG protein inhibits the reaction [icariin results in increased expression of RUNX2 mRNA]	18295595; 19747809;
C056599	icariin	icariin results in increased expression of RUNX2 mRNA	20019778
C499403	icaritin	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 mRNA]	30731080
C499403	icaritin	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 protein]	30731080
C499403	icaritin	icaritin results in increased expression of RUNX2 mRNA	30731080
C499403	icaritin	icaritin results in increased expression of RUNX2 protein	30731080
C016517	indole-3-carbinol	[indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of RUNX2 mRNA	22129741
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RUNX2 mRNA	25613284
C027681	isonicotinamide	isonicotinamide results in increased expression of RUNX2 mRNA	21745208
C016527	isoquercitrin	isoquercitrin results in increased expression of RUNX2 mRNA	30365939
C544151	jinfukang	Cisplatin promotes the reaction [jinfukang results in decreased expression of RUNX2 mRNA]	27392435
C544151	jinfukang	jinfukang promotes the reaction [Cisplatin results in decreased expression of RUNX2 mRNA]	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [BRD4 protein binds to RUNX2 gene]	25944566
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [BRD4 protein binds to RUNX2 promoter]	25307878
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of RUNX2 mRNA	23129625; 24646477; 24796395; 25307878; 25944566; 26752646; 26830473; 27432991;
C561695	(+)-JQ1 compound	RUNX2 mutant form promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]	25307878
C561695	(+)-JQ1 compound	RUNX2 protein inhibits the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]	25307878
C561695	(+)-JQ1 compound	RUNX2 protein results in decreased susceptibility to (+)-JQ1 compound	25307878
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of RUNX2 mRNA	24646477; 25944566;
C006552	kaempferol	kaempferol results in increased expression of RUNX2 mRNA	23989061
D007654	Ketoconazole	Ketoconazole inhibits the reaction [Calcifediol results in increased expression of RUNX2 mRNA]	21542014
D007656	Ketoglutaric Acids	Ketoglutaric Acids results in increased expression of RUNX2 mRNA	31051157
D007854	Lead	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 mRNA]	30731080
D007854	Lead	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 protein]	30731080
D007854	Lead	[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 mRNA	30731080
D007854	Lead	[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 protein	30731080
D007854	Lead	Lead results in decreased expression of RUNX2 mRNA	23086611
D007854	Lead	Lead results in decreased expression of RUNX2 protein	23086611
C017461	lead nitrate	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 mRNA]	30731080
C017461	lead nitrate	icaritin inhibits the reaction [[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 protein]	30731080
C017461	lead nitrate	[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 mRNA	30731080
C017461	lead nitrate	[lead nitrate results in increased abundance of Lead] which results in decreased expression of RUNX2 protein	30731080
C482199	lipopolysaccharide, E coli O55-B5	lipopolysaccharide, E coli O55-B5 inhibits the reaction [BMP2 protein results in increased expression of RUNX2 protein]	26961602
C482199	lipopolysaccharide, E coli O55-B5	MIR23B mRNA inhibits the reaction [lipopolysaccharide, E coli O55-B5 inhibits the reaction [BMP2 protein results in increased expression of RUNX2 protein]]	26961602
D019808	Losartan	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]	27412937
D019808	Losartan	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]	27412937
D058185	Magnetite Nanoparticles	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of RUNX2 mRNA	21641980
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of RUNX2 mRNA	26378955
C025340	manganese chloride	manganese chloride results in increased expression of RUNX2 mRNA	28801915
D008550	Melatonin	Melatonin results in increased expression of RUNX2 mRNA	20738756
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
D008687	Metformin	Metformin results in increased expression of RUNX2 protein	19594306
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RUNX2 mRNA	20938992
D008727	Methotrexate	RUNX2 mRNA results in decreased susceptibility to Methotrexate	20008919
D008731	Methoxychlor	Methoxychlor results in decreased expression of RUNX2 mRNA	23303685
D008731	Methoxychlor	Methoxychlor results in increased methylation of RUNX2 gene	23303685
C015358	methylparaben	methylparaben results in decreased expression of RUNX2 mRNA	28527915
D015735	Mifepristone	Mifepristone results in decreased expression of RUNX2 mRNA	20197312
D000077408	Modafinil	Alendronate promotes the reaction [Modafinil results in increased expression of RUNX2 mRNA]	29649498
D000077408	Modafinil	Modafinil results in increased expression of RUNX2 mRNA	29649498
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in decreased expression of RUNX2 mRNA	31059758
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in decreased expression of RUNX2 mRNA	22401849; 25777084;
C028577	monobutyl phthalate	monobutyl phthalate affects the expression of RUNX2 mRNA	24704097
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of RUNX2 mRNA	26924002
C093875	montelukast	montelukast results in increased expression of RUNX2 mRNA	19544365
C080955	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA	27050768
C080955	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein	27050768
C005274	naringin	DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]]	26482937
C005274	naringin	naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]	26482937
C005274	naringin	naringin results in increased expression of RUNX2 mRNA	24915843
C005274	naringin	naringin inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]	30878453
C005274	naringin	naringin results in increased expression of RUNX2 mRNA	21741227
C005274	naringin	Fulvestrant inhibits the reaction [naringin results in increased expression of RUNX2 mRNA]	23596885
C005274	naringin	naringin results in increased expression of RUNX2 mRNA	23596885
C553460	neoeriocitrin	neoeriocitrin results in increased expression of RUNX2 mRNA	21741227
D009536	Niacinamide	Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]	22539994
D009536	Niacinamide	Niacinamide results in decreased expression of RUNX2 protein	22539994
D009536	Niacinamide	Niacinamide results in increased acetylation of RUNX2 protein	22539994
D009536	Niacinamide	Resveratrol inhibits the reaction [Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]]	22539994
D009536	Niacinamide	Resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]	22539994
D009536	Niacinamide	Resveratrol inhibits the reaction [Niacinamide results in increased acetylation of RUNX2 protein]	22539994
D009536	Niacinamide	Niacinamide results in decreased expression of RUNX2 mRNA	16813520
D009536	Niacinamide	Niacinamide results in increased expression of RUNX2 mRNA	16813520
D009536	Niacinamide	[Resveratrol promotes the reaction [SIRT1 protein binds to RUNX2 protein]] inhibits the reaction [Niacinamide results in increased expression of PPARG]	22539994
D009536	Niacinamide	[Resveratrol results in decreased acetylation of RUNX2 protein] inhibits the reaction [Niacinamide results in increased expression of PPARG]	22539994
C028007	nickel monoxide	nickel monoxide results in increased expression of RUNX2 mRNA	19167457
D009534	Niclosamide	Niclosamide results in decreased expression of RUNX2 mRNA	28824321
C572573	N-nitroso-tris-chloroethylurea	N-nitroso-tris-chloroethylurea results in increased mutagenesis of RUNX2 gene	29484121
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	[zinc chloride co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in increased expression of RUNX2 protein	19913120
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	[zinc chloride deficiency co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in decreased expression of RUNX2 mRNA	19913120
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	[zinc chloride deficiency co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in decreased expression of RUNX2 protein	19913120
C072936	notoginsenoside R1	Fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA]	26362186
C072936	notoginsenoside R1	notoginsenoside R1 results in increased expression of RUNX2 mRNA	26362186
C434926	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]	26492236
C025589	ochratoxin A	ochratoxin A results in decreased expression of RUNX2 mRNA	30559759
C510784	ormosil	[ormosil binds to Polyethylene Glycols] which results in increased expression of RUNX2 mRNA	24888373
D010100	Oxygen	Oxygen deficiency results in decreased expression of RUNX2 mRNA	25596134
D019308	Palmitic Acid	acetovanillone inhibits the reaction [Palmitic Acid results in increased expression of RUNX2 mRNA]	24080574
D019308	Palmitic Acid	CYBA mutant form inhibits the reaction [Palmitic Acid results in increased expression of RUNX2 mRNA]	24080574
D019308	Palmitic Acid	Palmitic Acid results in increased expression of RUNX2 mRNA	24080574
D019308	Palmitic Acid	U 0126 inhibits the reaction [Palmitic Acid results in increased expression of RUNX2 mRNA]	24080574
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
D052638	Particulate Matter	Particulate Matter results in increased expression of RUNX2 mRNA	29703138
C410127	PCB 180	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of RUNX2 mRNA	25510870
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of RUNX2 mRNA	26272509
D010710	Phosphates	[Ascorbic Acid co-treated with Phosphates] results in increased expression of RUNX2 mRNA	21613385
D010710	Phosphates	Phosphates results in decreased expression of RUNX2 mRNA	26111760
D010936	Plant Extracts	Plant Extracts affects the expression of RUNX2 mRNA	24098073
C061957	polaprezinc	polaprezinc results in increased expression of RUNX2 mRNA	18327666
D011092	Polyethylene Glycols	[ormosil binds to Polyethylene Glycols] which results in increased expression of RUNX2 mRNA	24888373
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUNX2 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of RUNX2 mRNA	22079256
C013216	potassium phosphate	Fluorides inhibits the reaction [potassium phosphate results in increased expression of RUNX2 mRNA]	24561004
C013216	potassium phosphate	potassium phosphate results in increased expression of RUNX2 mRNA	24561004
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of RUNX2 mRNA	20660070
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [tanshinone results in increased expression of RUNX2 protein]	31306638
C432165	pyrazolanthrone	[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26136938
D011794	Quercetin	Quercetin results in increased expression of RUNX2 mRNA	16996034
D011794	Quercetin	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26053266; 26136938;
D011794	Quercetin	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26053266
D011794	Quercetin	[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26136938
D011794	Quercetin	Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]	27028516
D011794	Quercetin	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]	23117658
D011794	Quercetin	Quercetin results in increased expression of RUNX2 mRNA	17243115; 26053266; 26136938;
C004532	quinone	quinone results in increased expression of RUNX2 mRNA	22960397
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride affects the expression of RUNX2 mRNA	17166402
C073419	Remifemin	Remifemin affects the expression of RUNX2 mRNA	24098073
D000077185	Resveratrol	Resveratrol inhibits the reaction [Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]]	22539994
D000077185	Resveratrol	Resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]	22539994
D000077185	Resveratrol	Resveratrol inhibits the reaction [Niacinamide results in increased acetylation of RUNX2 protein]	22539994
D000077185	Resveratrol	Resveratrol inhibits the reaction [TNFSF11 protein results in decreased expression of RUNX2 protein]	21239502
D000077185	Resveratrol	Resveratrol promotes the reaction [[SIRT1 protein binds to EP300 protein] which binds to RUNX2 protein]	21239502
D000077185	Resveratrol	Resveratrol promotes the reaction [SIRT1 protein binds to RUNX2 protein]	21239502
D000077185	Resveratrol	Resveratrol results in decreased acetylation of RUNX2 protein	22539994
D000077185	Resveratrol	[Resveratrol results in increased activity of SIRT1 protein] promotes the reaction [SIRT1 protein binds to RUNX2 protein]	22539994
D000077185	Resveratrol	Resveratrol results in increased expression of RUNX2 protein	22539994
D000077185	Resveratrol	SIRT1 protein affects the reaction [Resveratrol results in decreased acetylation of RUNX2 protein]	22539994
D000077185	Resveratrol	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of RUNX2 mRNA]	17689939
D000077185	Resveratrol	Fulvestrant inhibits the reaction [Resveratrol results in increased expression of RUNX2 mRNA]	17689939
D000077185	Resveratrol	Resveratrol promotes the reaction [[SIRT1 protein binds to FOXO3 protein] which binds to RUNX2 3' UTR]	21713995
D000077185	Resveratrol	Resveratrol promotes the reaction [[[SIRT1 protein binds to FOXO3 protein] which binds to RUNX2 3' UTR] which results in increased expression of RUNX2 mRNA]	21713995; 21713995;
D000077185	Resveratrol	Resveratrol results in increased expression of RUNX2 mRNA	17689939; 21713995; 21745208;
D000077185	Resveratrol	Resveratrol results in increased expression of RUNX2 mRNA	19665018
D000077185	Resveratrol	Resveratrol results in increased expression of RUNX2 mRNA	16813520
D000077185	Resveratrol	[Resveratrol promotes the reaction [SIRT1 protein binds to RUNX2 protein]] inhibits the reaction [Niacinamide results in increased expression of PPARG]	22539994
D000077185	Resveratrol	[Resveratrol promotes the reaction [SIRT1 protein binds to RUNX2 protein]] which results in decreased activity of NCOR1 protein	22539994
D000077185	Resveratrol	[Resveratrol results in decreased acetylation of RUNX2 protein] inhibits the reaction [Niacinamide results in increased expression of PPARG]	22539994
D000077185	Resveratrol	[Resveratrol results in decreased acetylation of RUNX2 protein] which affects the activity of NCOR1 protein	22539994
C009172	rhodioloside	rhodioloside results in increased activity of RUNX2 protein	24055767
C009172	rhodioloside	rhodioloside results in increased expression of RUNX2 mRNA	24055767
D012256	Riboflavin	Riboflavin analog results in increased expression of RUNX2 protein	20688149
D000077154	Rosiglitazone	Rosiglitazone results in decreased expression of RUNX2	17993761
D000077154	Rosiglitazone	Rosiglitazone results in decreased expression of RUNX2 mRNA	12021203; 14500573; 23086663; 23322813; 25932594;
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of RUNX2 mRNA	15591153
D012402	Rotenone	Rotenone results in decreased expression of RUNX2 mRNA	29331484
C085746	rottlerin	rottlerin inhibits the reaction [FGF2 protein results in increased activity of RUNX2 protein]	12403780
C085746	rottlerin	rottlerin inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
C101044	RTKI cpd	RTKI cpd results in decreased expression of RUNX2 mRNA	20197312
C093642	SB 203580	[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]	26136938
D012822	Silicon Dioxide	Silicon Dioxide analog results in increased expression of RUNX2 mRNA	25895662
D019821	Simvastatin	Simvastatin results in increased expression of RUNX2	20381859
D019821	Simvastatin	DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]	22058016
D019821	Simvastatin	farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]	18310456
D019821	Simvastatin	geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]	18310456
D019821	Simvastatin	Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]	18310456
D019821	Simvastatin	Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]	18310456
D019821	Simvastatin	Simvastatin results in increased expression of RUNX2 mRNA	20417880; 22058016;
C017947	sodium arsenite	sodium arsenite results in increased expression of RUNX2 mRNA	29301061
C017947	sodium arsenite	sodium arsenite results in decreased expression of RUNX2 mRNA	28206643
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of RUNX2 mRNA	26339601
D012969	Sodium Fluoride	[Sodium Fluoride co-treated with Aluminum Chloride] results in increased expression of RUNX2 mRNA	21560300
D012969	Sodium Fluoride	DKK1 protein inhibits the reaction [Sodium Fluoride results in increased expression of RUNX2 mRNA]	24300170
D012969	Sodium Fluoride	DKK1 protein inhibits the reaction [Sodium Fluoride results in increased expression of RUNX2 protein]	24300170
D012969	Sodium Fluoride	Sodium Fluoride affects the expression of RUNX2 mRNA	25132241
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of RUNX2 mRNA	24300170
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of RUNX2 protein	24300170
D053260	Soot	Soot results in decreased expression of RUNX2 mRNA	23634900
D013311	Streptozocin	Streptozocin results in decreased expression of RUNX2 mRNA	25617479
C000615490	Strontium-90	Strontium-90 affects the expression of RUNX2 mRNA	23161408
D004113	Succimer	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of RUNX2 mRNA	21641980
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of RUNX2 mRNA	26378955
C446685	systhane	systhane affects the expression of RUNX2 mRNA	24704097
D016559	Tacrolimus	Tacrolimus results in decreased expression of RUNX2 mRNA	15780950
C061133	tamibarotene	tamibarotene results in decreased expression of RUNX2 mRNA	15498508
C021751	tanshinone	MIR322 mRNA inhibits the reaction [tanshinone results in increased expression of RUNX2 protein]	31306638
C021751	tanshinone	pyrazolanthrone inhibits the reaction [tanshinone results in increased expression of RUNX2 protein]	31306638
C021751	tanshinone	tanshinone results in increased expression of RUNX2 protein	31306638
C087114	tebuconazole	tebuconazole results in decreased expression of RUNX2 mRNA	30458266
C046393	tert-butylphenyl diphenyl phosphate	tert-butylphenyl diphenyl phosphate results in decreased expression of RUNX2 mRNA	30561715
C020806	tetrabromobisphenol A	tetrabromobisphenol A results in decreased expression of RUNX2 mRNA	25777084
D013749	Tetrachlorodibenzodioxin	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA]	23625689
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of RUNX2 mRNA	30203000
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA	22903824; 23625689; 26159488; 27913140;
D013749	Tetrachlorodibenzodioxin	AHR protein affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of RUNX2 mRNA]	19264158
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of RUNX2 mRNA	24704097
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to RUNX2 gene]	20819909
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of RUNX2 mRNA	19264158; 24058054;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA	17586704; 20819909; 27913140;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of RUNX2 mRNA	28077779
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of RUNX2 mRNA	19201780; 19264158;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA	27913140
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RUNX2 mRNA	25613284
D013893	Thiram	Thiram results in decreased expression of RUNX2 mRNA	24235232
D013893	Thiram	VEGFA protein affects the reaction [Thiram results in decreased expression of RUNX2 mRNA]	24235232
D013928	Thromboxane A2	Thromboxane A2 results in increased expression of RUNX2 mRNA	27050768
D013928	Thromboxane A2	Thromboxane A2 results in increased expression of RUNX2 protein	27050768
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of RUNX2 mRNA	18087596
D014212	Tretinoin	anacardic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA]	24819975
D014212	Tretinoin	ginkgolic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA]	24819975
D014212	Tretinoin	Tretinoin results in decreased expression of RUNX2 mRNA	15498508
D014212	Tretinoin	Tretinoin results in increased expression of RUNX2 mRNA	21934132; 24819975;
D014212	Tretinoin	Tretinoin results in increased expression of RUNX2 mRNA	16350840
C011559	tributyltin	tributyltin results in decreased expression of RUNX2 mRNA	23322813; 24513447; 25777084; 25932594;
C012589	trichostatin A	trichostatin A results in increased expression of RUNX2 mRNA	24935251
D014260	Triclosan	Triclosan results in increased expression of RUNX2 mRNA	30510588
C053549	triflumizol	triflumizol results in decreased expression of RUNX2 mRNA	23086663
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of RUNX2 mRNA	19042947
C005445	triphenyl phosphate	triphenyl phosphate results in decreased expression of RUNX2 mRNA	30561715
D000077288	Troglitazone	Troglitazone results in decreased expression of RUNX2 mRNA	16813520; 19122273;
D000077288	Troglitazone	Troglitazone inhibits the reaction [BMP2 protein results in increased expression of RUNX2 mRNA]	19122273
D014414	Tungsten	Tungsten results in decreased expression of RUNX2 mRNA	26865663
C113580	U 0126	U 0126 inhibits the reaction [Ascorbic Acid results in increased expression of RUNX2 mRNA]	20530736
C113580	U 0126	U 0126 inhibits the reaction [Palmitic Acid results in increased expression of RUNX2 mRNA]	24080574
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA	27188386
D014635	Valproic Acid	Valproic Acid results in decreased methylation of RUNX2 gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of RUNX2 mRNA	23179753; 24383497; 24935251; 26272509; 28001369;
D014635	Valproic Acid	Valproic Acid results in decreased expression of RUNX2 mRNA	23042728
D014638	Vanadates	Vanadates results in increased expression of RUNX2 mRNA	22714537
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of RUNX2 gene	25560391
D014801	Vitamin A	[Cryptoxanthins co-treated with Vitamin A] results in increased expression of RUNX2 mRNA	15962303
D014812	Vitamin K	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]	23117658
D014812	Vitamin K	[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA	23117658
D010837	Vitamin K 1	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]	27412937
D010837	Vitamin K 1	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]	27412937
D010837	Vitamin K 1	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA	27412937
D010837	Vitamin K 1	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein	27412937
D024482	Vitamin K 2	PTH protein promotes the reaction [Vitamin K 2 results in increased expression of RUNX2 protein]	30639440
D024482	Vitamin K 2	Vitamin K 2 affects the reaction [PTH protein results in increased expression of RUNX2 protein]	30639440
D024482	Vitamin K 2	Vitamin K 2 results in increased expression of RUNX2 protein	30639440
D014859	Warfarin	Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]	21910061
D014859	Warfarin	Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]	21910061
D014859	Warfarin	Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]	21910061
D014859	Warfarin	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]	27412937
D014859	Warfarin	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]	27412937
D014859	Warfarin	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]	23117658
D014859	Warfarin	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA	27412937
D014859	Warfarin	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein	27412937
D014859	Warfarin	[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA	23117658
D014859	Warfarin	SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]	29358327
D014859	Warfarin	SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]	29358327
D014859	Warfarin	[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA	29358327
D014859	Warfarin	[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein	29358327
D015032	Zinc	Zinc deficiency results in decreased expression of RUNX2 mRNA	21893222
D015032	Zinc	Zinc deficiency results in decreased expression of RUNX2 protein	21893222
C016837	zinc chloride	[zinc chloride co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in increased expression of RUNX2 protein	19913120
C016837	zinc chloride	[zinc chloride deficiency co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in decreased expression of RUNX2 mRNA	19913120
C016837	zinc chloride	[zinc chloride deficiency co-treated with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine] results in decreased expression of RUNX2 protein	19913120
D019287	Zinc Sulfate	Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]	18327666
D019287	Zinc Sulfate	Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]	18327666
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of RUNX2 mRNA	18327666
D000077211	Zoledronic Acid	Zoledronic Acid results in increased expression of RUNX2 mRNA	25596134

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0025	Alternative splicing
KW-0221	Differentiation
KW-0225	Disease mutation
KW-0238	DNA-binding
KW-1017	Isopeptide bond
KW-0488	Methylation
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0804	Transcription
KW-0805	Transcription regulation
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR000040	AML1_Runt
IPR008967	p53-like_TF_DNA-bd
IPR012346	p53/RUNT-type_TF_DNA-bd_sf
IPR013524	Runt_dom
IPR027384	Runx_central_dom_sf
IPR013711	RunxI_C_dom
IPR016554	TF_Runt-rel_RUNX

PROSITE

PROSITE ID	PROSITE Term
PS51062	RUNT

Pfam

Pfam ID	Pfam Term
PF00853	Runt
PF08504	RunxI

Gene: RUNX2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction